

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007729 A1

(51) International Patent Classification⁷: C12N 15/82,
A01H 1/00, C12N 15/40

[AU/AU]; 4 Ash Court, Mt Gravatt East, Queensland 4122 (AU).

(21) International Application Number:
PCT/AU2003/000919

(74) Agents: ARGAET, Victor, Peter et al.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, Queensland 4064 (AU).

(22) International Filing Date: 17 July 2003 (17.07.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/396,912 17 July 2002 (17.07.2002) US

(71) Applicant (*for all designated States except US*):
QUEENSLAND UNIVERSITY OF TECHNOLOGY [AU/AU]; Gardens Point Campus, 2 George Street, Brisbane, Queensland 4000 (AU).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): DALE, James, Langham [AU/AU]; 311 Priors Pocket Road, Moggill, Queensland 4070 (AU). HARDING, Robert, Maxwell [AU/AU]; 1/20 Sankey Street, Highgate Hill, Queensland 4101 (AU). BECKER, Douglas, Kenneth [AU/AU]; 20 Booker Street, Keperra, Queensland 4054 (AU). HAFNER, Gregory, John [AU/AU]; 80 Mountjoy Terrace, Wynnum, Queensland 4178 (AU). YANG, Ilin

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRANSCRIPTIONAL CONTROL ELEMENT, CHIMERIC CONSTRUCTS AND USES THEREFOR



(57) Abstract: Disclosed is a constitutive promoter for expression of endogenous coding sequences in plants, including dicotyledonous and monocotyledonous plants. Also disclosed is a chimeric construct, and transformed plant cells, plants and plant parts. The promoter is from the Taro bacilliform virus (TaBV), a badnavirus.. Methods for the diagnosis and treatment of viral infections, especially badnaviral infections are also disclosed. The genome of an isolate of TaBV and its encoded proteins is also disclosed.

BEST AVAILABLE COPY

WO 2004/007729 A1

**TRANSCRIPTIONAL CONTROL ELEMENT, CHIMERIC CONSTRUCTS
AND USES THEREFOR**

DT09 Rec'd PCT/PTO 18 JAN 2005

FIELD OF THE INVENTION

THIS INVENTION relates generally to transcriptional control elements for use in plant genetic engineering. More particularly, the present invention relates to a constitutive promoter for expression of foreign or endogenous coding sequences in plants, including dicotyledonous and monocotyledonous plants. The invention is also concerned with a chimeric nucleic acid construct comprising the promoter of the invention operably linked to a foreign or endogenous polynucleotide that codes for a protein of interest or a transcript capable of modulating expression of a target gene. The invention is further concerned with transformed plant cells, as well as differentiated plants and plant parts, containing the construct.

BACKGROUND OF THE INVENTION

A primary goal of genetic engineering is to obtain plants having improved characteristics or traits. Many different types of characteristics or traits are considered advantageous, but those of particular importance include resistance to plant diseases, resistance to viruses or insects and resistance to herbicides. Other advantageous characteristics or traits include tolerance to cold or soil salinity, enhanced stability or shelf life of the ultimate consumer product obtained from a plant, or improvement in the nutritional value of edible portions of a plant.

Recent advances in genetic engineering have enabled the incorporation of a selected gene (or genes) into plant cells to impart a desired quality (or qualities) to a plant of interest. The selected gene (or genes) may be derived from a source different from the plant of interest or may be native to the desired plant, but engineered to have different or improved qualities. This new gene (or genes) may then be expressed in cells of the regenerated plant to exhibit the new trait or characteristic.

In order for the newly incorporated gene to express the protein for which it codes in a plant cell, the proper regulatory signals must be present, in the proper location with respect to the gene. These regulatory signals include a promoter, a 5' non-translated leader sequence and a 3' polyadenylation signal.

The efficiency of gene expression is governed largely by the promoter used to express the gene. A promoter is typically a DNA sequence that directs the cellular machinery of a plant to produce (transcribe) RNA (transcript) from a contiguous transcribable region downstream (3') of the promoter. The promoter influences the rate at which the transcript of the gene is made. Assuming the transcript includes a coding region with appropriate translational signals, the

promoter also influences the rate at which the resultant protein product of the gene is produced. Promoter activity also can depend on the presence of several other *cis*-acting regulatory elements which, in conjunction with cellular factors, determine strength, specificity, and transcription initiation site (for a review, see Zawel and Reinberg, 1992, *Curr. Opin. Cell Biol.* 4: 488).

5 It has been shown that certain promoters are able to direct RNA synthesis at a higher rate relative to other promoters. These are called "strong promoters". Certain other promoters have been shown to direct RNA production at higher levels only in particular types of cells or tissues and are often referred to as "tissue-specific promoters". Promoters that are capable of directing RNA production in many or all tissues of a plant are called "constitutive promoters". Thus, expression of
10 a chimeric gene (or genes) introduced into a plant may potentially be controlled by identifying and using a promoter with the desired characteristics.

There have been numerous promoters described for gene expression in dicotyledonous plants. However, there still remains a dearth of promoters that can be used for effective expression of foreign or endogenous coding sequences in monocotyledonous plants.

15 One promoter that has been used widely for directing gene expression in, especially, dicotyledonous plants, is the 35S promoter derived from cauliflower mosaic virus (CaMV), a member of the family *Caulimoviridae*. CaMV is the source for both the 35S and 19S promoters, but the 35S promoter has been most widely used. It is capable of directing strong, constitutive expression in many dicotyledonous species and is generally functional, albeit with somewhat
20 reduced activity, in monocotyledonous plants (Benfey and Chua, *Science* 244:174-181, 1989; *Science* 250: 959-966, 1990; Fang *et al.*, *Plant Cell* 1:141-150, 1989; Fütterer *et al.*, *EMBO J* 9: 1697-1707, 1990; Terada and Shimamoto, *Mol. Gen Genet* 220:389-392, 1990).

In addition to the caulimoviruses, promoters have also been isolated from several badnaviruses including *Commelina yellow mottle virus*, *banana streak virus* and *sugarcane*
25 *bacilliform virus*. Badnaviruses are pararetroviruses, also classified in the family *Caulimoviridae*, genus *Badnavirus*. They have bacilliform-shaped virions approximately 30 x 130 nm encapsidating a circular dsDNA genome ranging from 7.1- 7.6 kbp that contains three open reading frames (ORFs) (Lockhart B.E.L. and Olszewski N.E. in Ganry J. (ed). *CIRAD/INIBAP*, Montpellier, 1993, pp. 105-113; Lockhart *et al.*, (eds). *Virus Taxonomy: Sixth Report of the International Committee*
30 *on the Taxonomy of Viruses*. Springer, Wien, 1995, pp. 185-188; Medberry *et al.*, *Nucleic Acids Research* 18:5505-5513, 1990.). Badnaviruses have been reported to infect a wide range of tropical plant species, including economically important monocotyledonous crops such as banana, sugarcane and rice.

Nevertheless, despite the existence of these representative promoters, there remains a
35 need to identify promoter sequences with improved efficacy and efficiency in directing the

expression of heterologous DNA sequences in all plant species and, in particular, in monocotyledonous plants.

SUMMARY OF THE INVENTION

The present invention is predicated in part on the recent sequencing, characterisation and classification of a Papua New Guinea isolate of Taro bacilliform virus (TaBV), which is associated with Alomae disease of taro (*Colocasia esculenta*), as a badnavirus, based on its non-enveloped, bacilliform virion morphology and transmission by mealybugs. The promoter region of this badnavirus, in particular, has been found quite unexpectedly to direct constitutive gene expression not only in dicotyledonous plant species but also in monocotyledonous plants, especially non-graminaceous monocotyledonous plants. The foregoing discovery has been reduced to practice in novel isolated DNA molecules, promoter regions, chimeric DNA constructs as well as plant cells and differentiated plants containing them, as described hereinafter.

Thus, in one aspect, the present invention provides an isolated DNA molecule comprising a promoter or biologically active fragment thereof or variant of these, wherein the promoter is located upstream of a transcribable DNA sequence that hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1.

Advantageously, the isolated promoter is of sufficient length such that it is capable of initiating and regulating transcription of a DNA sequence to which it is coupled. The promoter may be between about 250 nucleotides (nts) and 1200 nts in length and usually greater than 500 nts in length.

An analogous promoter can be obtained from an organism, especially from a virus, and more especially from a badnavirus, which has a DNA sequence that is capable of hybridising to a nucleic acid probe derived from the sequence set forth in SEQ ID NO:1 under at least low stringency conditions, especially under at least medium stringency conditions, and more especially under high stringency conditions.

The polynucleotide sequence set forth in SEQ ID NO:1 is a transcribable DNA sequence comprising three ORFs of the badnavirus, Taro bacilliform virus (TaBV). Such viruses are highly transcribed in tissue of infected monocotyledonous plants. Accordingly, nucleotide sequences that correspond or are complementary to at least a portion of the sequence set forth in SEQ ID NO:1 may be useful as probes for isolating homologous transcribable sequences from other organisms, especially from other viruses and more especially from other badnaviruses to, in turn, permit the isolation from those other organisms of promoters with analogous qualities to those described herein. In addition, these nucleotide sequences and their encoded amino acid sequences may be useful in diagnostic applications for detecting the presence of infecting virus particles in plants such as, for example, taro plants, e.g. using detectable agents which interact specifically with those nucleotide or amino acid sequences. Thus, in another aspect, the invention provides an isolated

polynucleotide comprising a nucleotide sequence that corresponds or is complementary to at least a portion of the sequence set forth in SEQ ID NO:1 or to a variant thereof. The variant suitably displays at least 30, 40, 50, 60, 70, 80, 90, 95% sequence identity to at least a portion of the sequence set forth in SEQ ID NO:1. Desirably, the variant hybridises to at least a portion of the sequence set forth in SEQ ID NO:1 under at least low stringency conditions, more desirably under at least medium stringency conditions, and even more desirably under high stringency conditions. Portions of SEQ ID NO:1, which are contemplated by the present invention, are suitably at least 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300 nucleotides in length.

In yet another aspect, the invention provides an isolated polypeptide comprising an amino acid sequence that corresponds to at least a portion of the sequence set forth in any of SEQ ID NO:3, 4 or 5, or of a variant that displays at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity to that sequence.

In some embodiments, the promoter comprises the sequence set forth in SEQ ID NO:6. In this embodiment, a biologically active fragment of the promoter is suitably selected from any one of the sequences set forth in SEQ ID NO:7, 8 and 9.

In some embodiments, a variant of the promoter has at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity to any one of the polynucleotides identified by SEQ ID NO:6, 7, 8 and 9. In another embodiment, a variant of the promoter is capable of hybridising to any one of the polynucleotides identified by SEQ ID NO:6, 7, 8 and 9 under at least low stringency conditions, especially under at least medium stringency conditions, and more especially under high stringency conditions.

Suitably, a promoter of the invention can be fused to a desired coding sequence to create a chimeric construct. This construct can then be introduced into a host cell, typically a plant cell or plant or plant part, by any method of choice. Accordingly, in another aspect of the invention, there is provided a chimeric DNA construct comprising an isolated promoter or biologically active fragment thereof or variant of these, wherein the promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1, wherein the promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed.

Suitably, the chimeric DNA construct further comprises a 3' non-translated sequence that is operably linked to the foreign or endogenous DNA sequence and that functions in plant cells to

terminate transcription and/or to cause addition of a polyadenylated nucleotide sequence to the 3' end of a transcribed RNA sequence.

5 The foreign or endogenous DNA sequence is foreign or endogenous with respect to the plant cell in which it is or will be introduced. In some embodiments, the foreign or endogenous DNA sequence encodes a structural or regulatory protein, or alternatively, a transcript capable of modulating expression of a corresponding target gene. In some embodiments, the transcript comprises an antisense RNA or a ribozyme or other transcribed region aimed at downregulation of expression of the corresponding target gene. For example, the other transcribed region may comprise a sense transcript aimed at sense suppression (co-suppression) of the corresponding target gene.

10 In some embodiments, depending upon the selected foreign or endogenous DNA sequence, the chimeric DNA construct may be further characterised in that the promoter or biologically active fragment or variant is capable of conferring transcription, especially high levels of transcription, of the foreign or endogenous DNA sequence in many or all tissues of a plant.

15 In still another aspect, the invention provides a method for expression of a foreign or endogenous DNA sequence, comprising introducing into a plant cell a chimeric DNA construct as broadly described above.

20 In a further aspect, the invention contemplates a method for producing a transformed plant cell, comprising introducing into a plant cell a chimeric DNA construct as broadly described above.

In still yet another aspect, the invention contemplates a method for producing transformed plant cells, comprising introducing into regenerable plant cells a chimeric DNA construct as broadly described above so as to yield transformed plant cells and identifying or selecting transformed plant cells.

25 In yet another aspect, the invention provides a method for selecting stable genetic transformants from transformed plant cells, comprising introducing into regenerable plant cells a chimeric DNA construct as broadly described above so as to yield transformed plant cells and identifying or selecting a transformed plant cell line from the transformed plant cells.

30 In some embodiments, the regenerable cells are regenerable dicotyledonous plant cells, usually monocotyledonous plant cells such as regenerable graminaceous monocotyledonous plant cells and especially regenerable non-graminaceous monocotyledonous plant cells. In some embodiments, the expression of the chimeric DNA construct in the transformed cells imparts a phenotypic characteristic to the transformed cells.

According to another aspect of the invention, there is provided a transformed plant cell containing a chimeric DNA construct as broadly described above.

In still another aspect, the invention contemplates a method for producing a differentiated transgenic plant, comprising introducing a chimeric DNA construct as broadly described above into
5 regenerative plant cells so as to yield regenerable transformed cells, identifying or selecting a population of transformed cells, and regenerating a differentiated transgenic plant from the population.

In some embodiments, the expression of the chimeric DNA construct renders the differentiated transgenic plant identifiable over the corresponding non-transgenic plant.

10 In still a further aspect, the invention provides a differentiated transgenic plant comprising plant cells containing a chimeric DNA construct as broadly described above.

The chimeric DNA construct is transmitted through a complete cycle of the differentiated transgenic plant to its progeny so that it is expressed by the progeny plants. Thus, the invention also provides seed, other plant parts, tissue, and progeny plants derived from the differentiated
15 transgenic plant.

The invention also extends to a method for diagnosing a badnaviral infection of a plant, comprising detecting the presence in a cell or tissue of the plant of (a) a nucleotide sequence that corresponds or is complementary to at least a portion of the nucleotide sequence set forth in SEQ ID NO:1 or 2, or of a variant of the nucleotide sequence, or (b) an amino acid sequence that
20 corresponds to at least a portion of the sequence set forth in SEQ ID NO:3, 4 or 5, or of a variant of the amino acid sequence.

The badnaviral nucleic acid and amino acid sequences described herein can also be used to screen for drugs which modulate one or more of their activities, and which would be useful for the treatment and/or prevention of badnavirus infections. Thus, in yet another aspect of the
25 invention there is provided a method of screening for an agent that modulates badnaviral infection, the method comprising:

- contacting a preparation comprising:

- (i) a polypeptide comprising an amino acid sequence that corresponds to at least a portion of the sequence set forth in SEQ ID NO: 3, 4 or 5, or of a variant of the sequence; or
30 (ii) a polynucleotide comprising a nucleotide sequence that corresponds or is complementary to at least a portion of the sequence set forth in SEQ ID NO:1 or 2, which polynucleotide is operably linked to a promoter; or
(iii) a polynucleotide comprising a reporter gene that is operably connected to a promoter comprising the sequence set forth in SEQ ID NO:6, 7, 8 or 9,

with a test agent; and

- detecting a change in the level and/or functional activity of the polypeptide, or an expression product of the nucleotide sequence or of the reporter gene, relative to a normal or reference level and/or functional activity in the absence of the test agent.

5 In some embodiments, the agent inhibits or reduces badnavirus infection. In this instance, the method is further characterised by detecting a reduction in the level and/or functional activity of the polypeptide, or an expression product of the nucleotide sequence or of the reporter gene, relative to the normal or reference level and/or functional activity.

10 In another aspect, the invention provides a method for treating and/or preventing badnaviral infection of a plant, comprising administering to the plant an agent that:

- reduces the level and/or functional activity of:

a polypeptide that comprises an amino acid sequence corresponding to at least a portion of the sequence set forth in SEQ ID NO: 3, 4 or 5, or of a variant of that sequence;
or

15 an expression product of a nucleotide sequence that corresponds or is complementary to at least a portion of the sequence set forth in SEQ ID NO:1 or 2; or

- reduces the functional activity of a promoter that comprises the sequence set forth in any one of SEQ ID NO:6, 7, 8 or 9.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagrammatic representation of the genome organisation of TaBV. The positions of ORF 1, ORF 2, and ORF 3 are shown. The location of the putative met tRNA binding site, putative movement protein domains, RNA binding domain (RB), cysteine-rich region, conserved aspartic protease domain, conserved reverse transcriptase domains and conserved RNAse H domains are indicated. Positions for designing primers Badna FP, Badna RP, TRBR, 5F (starts at nucleotide 7,344), 1F (starts at nucleotide 5,534) and G2R (starts at nucleotide 5,556) are indicated by FP, RP, R, a, b, and c, respectively.

Figure 2 is a diagrammatic representation of the TaBV genomic region, from which the TaBV promoter fragments were derived. Positions and sequences of a region resembling the CaMV 35S promoter as-1 element and of putative TATA box and tRNA^{met} binding site are indicated by dash lines. The predicted position of open reading frame 1 (ORF 1) and ORF 3 are also indicated. All promoter fragments within bracket A were created with restriction sites as indicated by labelled boxes, except for the *Xba*I site which exists within the native TaBV sequence. Promoter fragments within bracket B were generated by directional cloning of fragments in bracket A, as indicated by grey arrows using indicated restriction sites. Promoter fragment T600L was generated by removal of the *Pst* I/ *Xba* I fragment from T1200L and, in the process, destroying the *Xba* I site.

Figure 3 is a schematic representation of plasmids used for either comparison of commonly used promoters with TaBV derived promoters and/or as selectable markers. Ubi-1 = promoter region from maize polyubiquitin-1 gene, Ubi-1 intron = first exon and intron from maize polyubiquitin-1 gene, GFP = gene coding for green fluorescent protein, nos 3' = 3' untranslated region from gene coding for *Agrobacterium tumefaciens* nopaline synthase, CaMV 35S = promoter region from gene coding for cauliflower mosaic virus (CaMV) 35S RNA, uidA = gene coding for β -glucuronidase (GUS), RbcS 3' = 3' untranslated region from gene coding for *Nicotiana tabacum* rubisco, BT6.3 = promoter region from DNA-6 from banana bunchy top virus (Dugdale et al 1998), *np1II* = gene coding for neomycin phosphotransferase, 35S 3' = 3' untranslated region from gene coding for CaMV virus 35S RNA, D35S = double CaMV 35S promoter, RB = right border of binary vector T-DNA region, LB = left border of binary vector T-DNA region.

Figure 4 is a photographic representation showing transient expression of *uidA* and GFP in taro directed by *ubi1* promoter plus *ubi1* intron (1, 2), CaMV 35S promoter (3, 4) and T600 promoter (5, 6).

Figure 5 is a histogram representing a comparison of transient promoter activity of TaBV-derived promoters with the maize polyubiquitin promoter (Ubi; in pUGR73) and the CaMV 35S promoter (35S; in pGUS2) in taro leaf using the *uidA* reporter gene. *In vitro*-grown taro leaves

were bombarded with expression vectors and promoter activity assayed by GUS fluorometric assay 72h post-bombardment. Values are expressed as the mean value of four replicates for each promoter construct, in nmol MU/min/mg total soluble protein, \pm the standard error. TaBV derived promoters examined included T500 (in pT500-GUS), T600 (in pT600-GUS), T1200 (in pT1200GUS) and T1200L (in pT1200L-GUS). Non-bombarded leaves (untransformed) were also included a control for endogenous GUS activity.

Figure 6 is a photographic representation showing GFP expression in the roots and leaves of transgenic banana directed by the CaMV 35S promoter (1, 2), T1200 promoter (3, 4), T600 promoter (5, 6) and T500 promoter (7, 8).

Figure 7 is a histogram representing a comparison of TaBV derived promoter activity with the maize polyubiquitin promoter (Ubi; in pUGR73) in stably transformed banana leaf using the *uidA* reporter gene. Banana leaves from plants derived from independent transformation events (between 4 and 12 for each promoter construct) were assayed by GUS fluorometric assay. Values are expressed as the mean value, in nmol MU/min/mg total soluble protein, \pm the standard error. TaBV derived promoters examined included T500 (in pT500-GUS), T600 (in pT600-GUS), T1200 (in pT1200-GUS). Non-bombarded leaves (untransformed) were also included a control for endogenous GUS activity.

Figure 8 is a photographic representation showing expression of *uidA* in transgenic tobacco directed by the CaMV 35S promoter (1, 2), T1200 promoter (3, 4), T600 promoter (5, 6) and T500 promoter (7, 8). (9) Leaf and root of untransformed tobacco showed no *uidA* expression. (10) Transgenic tobacco showed GFP expression in newly emerging young leaves and roots.

Figure 9 is a histogram representing a comparison of TaBV derived promoter activity with the double CaMV promoter (D35S; in p2302) in stably transformed tobacco leaf using the *uidA* reporter 35S gene. Tobacco leaves from plants derived from independent transformation events (between 5 and 7 for each promoter construct) were assayed by GUS fluorometric assay. Values are expressed as the mean value, in nmol MU/min/mg total soluble protein, \pm the standard error. TaBV derived promoters examined included T500 (in pCambiaT500-GUS), T600 (in pCambiaT600-GUS), T1200 (in pCambiaT1200-GUS). Non-bombarded leaves (untransformed) were also included a control for endogenous GUS activity.

BRIEF DESCRIPTION OF THE SEQUENCES: SUMMARY TABLE

TABLE A

<i>Sequence ID Number</i>	<i>Sequence</i>	<i>Length</i>
SEQ ID NO:1	Genomic sequence of Papua New Guinea isolate of Taro bacilliform virus encoding ORFs 1, 2 and 3	6520 nts
SEQ ID NO:2	Entire genomic sequence of Papua New Guinea isolate of Taro bacilliform virus.	7458 nts
SEQ ID NO:3	Putative Polypeptide product ORF 1, encoded by nucleotides 353 – 793 of SEQ ID NO:1	146 aa
SEQ ID NO:4	Putative Polypeptide product ORF 2, encoded by nucleotides 792 – 1227 of SEQ ID NO:1	144 aa
SEQ ID NO:5	Putative Polypeptide product ORF 3, encoded by nucleotides 1230 – 6872 of SEQ ID NO:1	1881 aa
SEQ ID NO:6	Polynucleotide representing promoter region 6281-12, designated T1200	1190 nts
SEQ ID NO:7	Polynucleotide representing promoter region 6873-12, designated T600	598 nts
SEQ ID NO:8	Polynucleotide representing promoter region 6942-12, designated T500	529 nts
SEQ ID NO:9	Polynucleotide representing promoter region 7210-12, designated T250	261 nts
SEQ ID NO:10	Badna FP primer	23 nts
SEQ ID NO:11	Badna RP primer	24 nts
SEQ ID NO:12	1F primer	23 nts
SEQ ID NO:13	TRBR primer	26 nts
SEQ ID NO:14	5F primer	22 nts
SEQ ID NO:15	G2R primer	25 nts
SEQ ID NO:16	cytoplasmic initiator methionine tRNA (tRNA ^{met}) binding site	12 nts
SEQ ID NO:17	F-GTN primer	25 nts
SEQ ID NO:18	R-GTN primer	24 nts

<i>Sequence ID Number</i>	<i>Sequence</i>	<i>Length</i>
SEQ ID NO:19	P527-F primer	20 nts
SEQ ID NO:20	P257-F primer	23 nts
SEQ ID NO:21	P114-F primer	23 nts
SEQ ID NO:22	FP-as-1 primer	24 nts
SEQ ID NO:23	TRBR-Bam primer	24 nts
SEQ ID NO:24	FP-6765-pro primer	21 nts
SEQ ID NO:25	P600Not-F primer	28 nts
SEQ ID NO:26	P600Bgl-R primer	30 nts
SEQ ID NO:27	RP-leader primer	27 nts
SEQ ID NO:28	GUS1 primer	15 nts
SEQ ID NO:29	GUS2 primer	12 nts

nts = nucleotides; aa = amino acids

DETAILED DESCRIPTION OF THE INVENTION

1. Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For the purposes of the present invention, the following terms are defined below.

The articles "*a*" and "*an*" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "*an element*" means one element or more than one element.

The term "*about*" is used herein to refer to sequences that vary by as much as 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10% to the length of a reference sequence.

"*Amplification product*" refers to a nucleic acid product generated by nucleic acid amplification techniques.

By "*antigen-binding molecule*" is meant a molecule that has binding affinity for a target antigen. It will be understood that this term extends to immunoglobulins, immunoglobulin fragments and non-immunoglobulin derived protein frameworks that exhibit antigen-binding activity.

As used herein, the term "*binds specifically*" and the like refers to antigen-binding molecules that bind the polypeptide or polypeptide fragments of the invention but do not significantly bind to homologous prior art polypeptides.

The term "*biologically active fragment*", as applied to promoter sequences, refers to a fragment that has at least about 0.1, 0.5, 1, 2, 5, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30% of the activity of a reference promoter sequence. It will also be understood that the phrase "*biologically active fragment*" refers to a part of an indicated DNA sequence that initiates RNA transcription or that, when fused to a particular gene and introduced into a plant cell, causes expression of the gene at a level higher than is possible in the absence of such part of the indicated DNA sequence. Included within the scope of the present invention are biologically active fragments of at least about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300 nucleotides in length. Alternatively, the term "*biologically active fragment*", as applied to polypeptides of the invention, includes deletion mutants and small peptides, for example of at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 contiguous amino acid residues, which comprise an activity of a parent polypeptide.

The terms "*chimeric construct*" or "*chimeric DNA*" and the like are used herein to refer to a gene or DNA sequence or segment comprising at least two DNA sequences or segments from species which do not combine DNA under natural conditions, or which DNA sequences or segments are positioned or linked in a manner which does not normally occur in the native genome of the untransformed plant.

Throughout this specification, unless the context requires otherwise, the words "*comprise*", "*comprises*" and "*comprising*" will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements.

"*Constitutive promoter*" refers to a promoter that directs expression of an operably linked transcribable sequence in many or all tissues of a plant.

By "*corresponds to*" or "*corresponding to*" is meant a polynucleotide (a) having a nucleotide sequence that is substantially identical or complementary to all or a portion of a reference polynucleotide sequence or (b) encoding an amino acid sequence identical to an amino acid sequence in a peptide or protein. This phrase also includes within its scope a peptide or polypeptide having an amino acid sequence that is substantially identical to a sequence of amino acids in a reference peptide or protein.

The terms "*growing*" or "*regeneration*" as used herein mean growing a whole, differentiated plant from a plant cell, a group of plant cells, a plant part (including seeds), or a plant piece (e.g., from a protoplast, callus, or tissue part).

"*Hybridisation*" is used herein to denote the pairing of complementary nucleotide sequences to produce a DNA-DNA hybrid or a DNA-RNA hybrid. Complementary base sequences are those sequences that are related by the base-pairing rules. In DNA, A pairs with T and C pairs with G. In RNA U pairs with A and C pairs with G. In this regard, the terms "match" and "mismatch" as used herein refer to the hybridisation potential of paired nucleotides in complementary nucleic acid strands. Matched nucleotides hybridise efficiently, such as the classical A-T and G-C base pair mentioned above. Mismatches are other combinations of nucleotides that do not hybridise efficiently.

By "*isolated*" is meant material that is substantially or essentially free from components that normally accompany it in its native state. For example, an "*isolated polynucleotide*", as used herein, refers to a polynucleotide, which has been purified from the sequences which flank it in a naturally occurring state, e.g., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment.

By "*marker gene*" is meant a gene that imparts a distinct phenotype to cells expressing the marker gene and thus allows such transformed cells to be distinguished from cells that do not have the marker. A selectable marker gene confers a trait for which one can 'select' based on resistance to a selective agent (e.g., a herbicide, antibiotic, radiation, heat, or other treatment
5 damaging to untransformed cells). A screenable marker gene (or reporter gene) confers a trait that one can identify through observation or testing, i.e., by 'screening' (e.g. β -glucuronidase, luciferase, or other enzyme activity not present in untransformed cells).

By "*obtained from*" is meant that a sample such as, for example, a nucleic acid extract is isolated from, or derived from, a particular source of the host. For example, the nucleic acid extract
10 may be obtained from tissue isolated directly from the host.

The term "*oligonucleotide*" as used herein refers to a polymer composed of a multiplicity of nucleotide units (deoxyribonucleotides or ribonucleotides, or related structural variants or synthetic analogues thereof) linked via phosphodiester bonds (or related structural variants or synthetic analogues thereof). Thus, while the term "*oligonucleotide*" typically refers to a nucleotide
15 polymer in which the nucleotides and linkages between them are naturally occurring, it will be understood that the term also includes within its scope various analogues including, but not restricted to, peptide nucleic acids (PNAs), phosphoramidates, phosphorothioates, methyl phosphonates, 2-O-methyl ribonucleic acids, and the like. The exact size of the molecule may vary depending on the particular application. An oligonucleotide is typically rather short in length,
20 generally from about 10 to 30 nucleotides, but the term can refer to molecules of any length, although the term "*polynucleotide*" or "*nucleic acid*" is typically used for large oligonucleotides.

The term "*operably connected*" or "*operably linked*" as used herein means placing a structural gene under the regulatory control of a promoter, which then controls the transcription and optionally translation of the gene. In the construction of heterologous promoter/structural gene
25 combinations, it is generally preferred to position the genetic sequence or promoter at a distance from the gene transcription start site that is approximately the same as the distance between that genetic sequence or promoter and the gene it controls in its natural setting; i.e. the gene from which the genetic sequence or promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of function. Similarly, the preferred positioning of a regulatory
30 sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting; i.e. the genes from which it is derived.

As used herein, "*plant*" and "*differentiated plant*" refer to a whole plant or plant part containing differentiated plant cell types, tissues and/or organ systems. Plantlets and seeds are also included within the meaning of the foregoing terms. Plants included in the invention are any plants

amenable to transformation techniques, including angiosperms, gymnosperms, monocotyledons and dicotyledons.

The term "*plant cell*" as used herein refers to any plant cell or cell line including protoplasts, gamete-producing cells, and cells which regenerate into whole plants. Plant cells also
5 include cells in plants as well as protoplasts in culture.

By "*plant tissue*" is meant differentiated and undifferentiated tissue derived from roots, shoots, pollen, seeds, tumour tissue, such as crown galls, and various forms of aggregations of plant cells in culture, such as embryos and calluses.

The term "*polynucleotide*" or "*nucleic acid*" as used herein designates mRNA, RNA, cRNA, cDNA or DNA. The term typically refers to oligonucleotides greater than 30 nucleotides in
10 length.

The terms "*polynucleotide variant*" and "*variant*" and the like refer to polynucleotides displaying substantial sequence identity with a reference polynucleotide sequence or polynucleotides that hybridise with a reference sequence under stringent conditions that are defined
15 hereinafter. These terms also encompass polynucleotides that are distinguished from a reference polynucleotide by the addition, deletion or substitution of at least one nucleotide. Accordingly, the terms "*polynucleotide variant*" and "*variant*" include polynucleotides in which one or more nucleotides have been added or deleted, or replaced with different nucleotides. In this regard, it is well understood in the art that certain alterations inclusive of mutations, additions, deletions and
20 substitutions can be made to a reference polynucleotide whereby the altered polynucleotide retains the biological function or activity of the reference polynucleotide. Accordingly, these terms encompass polynucleotides that initiate RNA transcription or that, when fused to a particular gene and introduced into a plant cell, cause expression of the gene at a level higher than is possible in the absence of such polynucleotides. The terms "*polynucleotide variant*" and "*variant*" also include
25 naturally occurring allelic variants.

"*Polypeptide*", "*peptide*" and "*protein*" are used interchangeably herein to refer to a polymer of amino acid residues and to variants and synthetic analogues of the same. Thus, these terms apply to amino acid polymers in which one or more amino acid residues is a synthetic non-naturally occurring amino acid, such as a chemical analogue of a corresponding naturally occurring
30 amino acid, as well as to naturally-occurring amino acid polymers.

The term "*polypeptide variant*" refers to polypeptides that are distinguished from a reference polypeptide by the addition, deletion or substitution of at least one amino acid. In certain embodiments, a polypeptide variant is distinguished from a reference polypeptide by one or more substitutions, which may be conservative or non-conservative. In certain embodiments, the

polypeptide variant comprises conservative substitutions and, in this regard, it is well understood in the art that some amino acids may be changed to others with broadly similar properties without changing the nature of the activity of the polypeptide. Polypeptide variants also encompass polypeptides in which one or more amino acids have been added or deleted, or replaced with
5 different amino acid residues.

By "*primer*" is meant an oligonucleotide which, when paired with a strand of DNA, is capable of initiating the synthesis of a primer extension product in the presence of a suitable polymerising agent. The primer is typically single-stranded for maximum efficiency in amplification but may alternatively be double-stranded. A primer must be sufficiently long to prime
10 the synthesis of extension products in the presence of the polymerisation agent. The length of the primer depends on many factors, including application, temperature to be employed, template reaction conditions, other reagents, and source of primers. For example, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15 to 35 or more nucleotides, although it may contain fewer nucleotides. Primers can be large polynucleotides, such
15 as from about 200 nucleotides to several kilobases or more. Primers may be selected to be "substantially complementary" to the sequence on the template to which it is designed to hybridise and serve as a site for the initiation of synthesis. By "substantially complementary", it is meant that the primer is sufficiently complementary to hybridise with a target nucleotide sequence. Suitably, the primer contains no mismatches with the template to which it is designed to hybridise but this is
20 not essential. For example, non-complementary nucleotides may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the template. Alternatively, non-complementary nucleotides or a stretch of non-complementary nucleotides can be interspersed into a primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridise therewith and thereby form a template for synthesis
25 of the extension product of the primer.

"*Probe*" refers to a molecule that binds to a specific sequence or sub-sequence or other moiety of another molecule. Unless otherwise indicated, the term "probe" typically refers to a polynucleotide probe that binds to another nucleic acid, often called the "target nucleic acid", through complementary base pairing. Probes may bind target nucleic acids lacking complete
30 sequence complementarity with the probe, depending on the stringency of the hybridisation conditions. Typically, probes comprise at least 15, 20, 30, 50, 100, 200, 400, 600, 1000 nucleotides. Probes can be labelled directly or indirectly.

The term "*recombinant polynucleotide*" as used herein refers to a polynucleotide formed *in vitro* by the manipulation of nucleic acid into a form not normally found in nature. For example,
35 the recombinant polynucleotide may be in the form of an expression vector. Generally, such

expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleotide sequence.

By "*promoter*" is meant a sequence of nucleotides from which transcription of DNA operably linked downstream of said sequence (i.e. in the 3' direction on the sense strand of double-stranded DNA) may be initiated.

By "*recombinant polypeptide*" is meant a polypeptide made using recombinant techniques, i.e., through the expression of a recombinant polynucleotide.

Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity" and "substantial identity". A "*reference sequence*" is at least 12 but frequently 15 to 18 and often at least 25 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e., only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "*comparison window*" refers to a conceptual segment of at least 50 contiguous positions, usually about 50 to about 100, more usually about 100 to about 150 in which a sequence is compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. The comparison window may comprise additions or deletions (i.e., gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerised implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e., resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as for example disclosed by Altschul *et al.*, 1997, *Nucl. Acids Res.* 25:3389. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel *et al.*, "Current Protocols in Molecular Biology", John Wiley & Sons Inc, 1994-1998, Chapter 15.

The terms "*sequence identity*" and "*identity*" are used interchangeably herein to refer to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a "*percentage of sequence identity*" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, I) or

- the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software.
- 10 The term "sequence similarity" and "similarity" are used interchangeably herein to refer to the percentage number of amino acids that are identical or constitute conservative substitutions as defined in the following table.

TABLE A

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala	Val, Leu, Ile	Val
Arg	Lys, Gln, Asn	Lys
Asn	Gln, His, Lys, Arg	Gln
Asp	Glu	Glu
Cys	Ser	Ser
Gln	Asn, His, Lys,	Asn
Glu	Asp, Lys	Asp
Gly	Pro	Pro
His	Asn, Gln, Lys, Arg	Arg
Ile	Leu, Val, Met, Ala, Phe, Norleu	Leu
Leu	Norleu, Ile, Val, Met, Ala, Phe	Ile
Lys	Arg, Gln, Asn	Arg
Met	Leu, Ile, Phe	Leu
Phe	Leu, Val, Ile, Ala	Leu
Pro	Gly	Gly
Ser	Thr	Thr

<i>Original Residue</i>	<i>Exemplary Substitutions</i>	<i>Preferred Substitutions</i>
Thr	Ser	Ser
Trp	Tyr	Tyr
Tyr	Trp, Phe, Thr, Ser	Phe
Val	Ile, Leu, Met, Phe, Ala, Norleu	Leu

Similarity may be determined using sequence comparison programs such as GAP (Deveraux *et al.* 1984, *Nucleic Acids Research* 12:387-395). In this way, sequences of a similar or substantially different length to those cited herein might be compared by insertion of gaps into the alignment, such gaps being determined, for example, by the comparison algorithm used by GAP.

5 “Stringency” as used herein, refers to the temperature and ionic strength conditions, and presence or absence of certain organic solvents, during hybridisation. The higher the stringency, the higher will be the degree of complementarity between immobilised nucleotide sequences and the labelled polynucleotide sequence.

10 “Stringent conditions” refers to temperature and ionic conditions under which only nucleotide sequences having a high frequency of complementary bases will hybridise. The stringency required is nucleotide sequence dependent and depends upon the various components present during hybridisation. Generally, stringent conditions are selected to be about 10 to 20° C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a target
15 sequence hybridises to a complementary probe.

 The term “*transcribable DNA sequence*” or “*transcribed DNA sequence*”, excludes the non-transcribed regulatory sequence that drives transcription. Depending on the aspect of the invention, the *transcribable* sequence may be derived in whole or in part from any source known to the art, including a plant, a fungus, an animal, a bacterial genome or episome, eukaryotic, nuclear
20 or plasmid DNA, cDNA, viral DNA or chemically synthesised DNA. A *transcribable* sequence may contain one or more modifications in either the coding or the untranslated regions, which could affect the biological activity or the chemical structure of the expression product, the rate of expression or the manner of expression control. Such modifications include, but are not limited to, insertions, deletions and substitutions of one or more nucleotides. The *transcribable* sequence may
25 contain an uninterrupted coding sequence or it may include one or more introns, bound by the appropriate splice junctions. The *transcribable* sequence may also encode a fusion protein. It is contemplated that introduction into plant tissue of chimeric nucleic acid constructs of the invention

will include constructions wherein the *transcribable* sequence and its promoter are each derived from different species.

The term "*transformation*" means alteration of the genotype of a host plant by the introduction of a chimeric nucleic acid.

5 The term "*transgene*" is used herein to describe genetic material that has been or is about to be artificially inserted into the genome of a cell, particularly a plant cell. The transgene is used to transform a cell, meaning that a permanent or transient genetic change, especially a permanent genetic change, is induced in a cell following incorporation of a chimeric DNA construct as defined herein. A permanent genetic change is generally achieved by introduction of the DNA into the
10 genome of the cell.

As used herein, the term "*transgenic*" or "*transformed*" with respect to a plant cell, plant part (including seed), plant tissue or plant means a plant cell, plant part, plant tissue or plant which comprises an isolated chimeric DNA construct according to the invention which has been introduced into the nucleome, especially the genome, of a plant cell, plant part, plant tissue or
15 plant.

By "*transgenote*" is meant an immediate product of a transformation process.

By "*vector*" is meant a nucleic acid molecule, suitably a DNA molecule derived, for example, from a plasmid, bacteriophage, or plant virus, into which a nucleic acid sequence may be inserted or cloned. A vector typically contains one or more unique restriction sites and may be
20 capable of autonomous replication in a defined host cell including a target cell or tissue or a progenitor cell or tissue thereof, or be integrable with the genome of the defined host such that the cloned sequence is reproducible. Accordingly, the vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a linear or closed circular plasmid, an
25 extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. A vector system may comprise a single vector or plasmid, two or more vectors or plasmids, which together contain the total DNA to be introduced
30 into the genome of the host cell, or a transposon. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may also include a selection marker such as an antibiotic resistance gene that can be used for selection of suitable transformants. Examples of such resistance genes are well known to those of skill in the art.

The terms "wild type", "native" or "non-transgenic" refers to an untransformed plant cell, plant part, plant tissue or plant, i.e. one where the nucleome, especially the genome, has not been altered by the presence of a chimeric DNA construct as defined herein.

2. *Transcribed DNA sequence*

5 The promoter of the present invention was derived from a Papua New Guinea isolate of the badnavirus Taro Bacilliform virus (TaBV), which infects taro plants (*Colocasia esculenta*). The entire sequence of its circular genome, which is set forth in SEQ ID NO:2, extends 7458 nts and comprises three open reading frames (ORF). ORF 1 extends from position 350 through 790; ORF 2 extends from position 790 through 1224, and ORF 3 extends from position 1227 through 6872. For
10 convenience, the nucleotide sequence corresponding to these open reading frames is presented in SEQ ID NO:1. An untranslated region (UTR) extends from nucleotide 6873 through nucleotide 349 of SEQ ID NO:2.

 The open reading frames of the subject TaBV are highly transcribed in infected tissue of taro. Accordingly, nucleic acid sequences corresponding to these open reading frames may be
15 useful as probes for isolating homologous sequences from other organisms including, but not limited to, viruses such as badnaviruses. These homologous sequences, in turn, permit the isolation of promoters from such other organisms, which have the same or similar constitutive qualities as the promoter sequences exemplified herein. Further, the homologous sequences and their encoded amino acid sequences are useful in diagnostic applications for detecting the presence of infecting
20 virus particles in plants such as, for example, taro plants. Applications of this type include the use of detectable agents such as probes and antigen-binding molecules, which interact specifically with those sequences.

3. *Polynucleotide sequence variants of transcribed DNA sequences*

 In general, homologous sequences or polynucleotide sequence variants of the invention
25 comprise regions that show suitably at least 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity over a reference polynucleotide sequence of identical size ("comparison window") or when compared to an aligned sequence in which the alignment is
30 performed by a computer homology program known in the art.

 Polynucleotide sequence variants of the invention may be prepared according to the following procedure:

- (a) obtaining a nucleic acid extract from a suitable organism, which is preferably a virus, and more preferably a badnavirus;

(b) creating primers which are optionally degenerate wherein each comprises a portion of a reference polynucleotide corresponding to a transcribable DNA sequence of the invention; and

(c) using said primers to amplify, *via* nucleic acid amplification techniques, at least one amplification product from said nucleic acid extract, wherein said amplification product
5 corresponds to a polynucleotide sequence variant.

Suitable nucleic acid amplification techniques are well known to the skilled addressee, and include polymerase chain reaction (PCR) as for example described in Ausubel *et al.* (*supra*); strand displacement amplification (SDA) as for example described in U.S. Patent No 5,422,252; rolling circle replication (RCR) as for example described in Liu *et al.*, (1996, *J. Am. Chem. Soc.*
10 118:1587-1594 and International application WO 92/01813) and Lizardi *et al.*, (International Application WO 97/19193) nucleic acid sequence-based amplification (NASBA) as for example described by Sooknanan *et al.*, (1994, *Biotechniques* 17:1077-1080); and Q- β replicase amplification as for example described by Tyagi *et al.*, (1996, *Proc. Natl. Acad. Sci. USA* 93:5395-5400).

Typically, polynucleotide sequence variants that are substantially complementary to a reference polynucleotide are identified by blotting techniques that include a step whereby nucleic acids are immobilised on a matrix (preferably a synthetic membrane such as nitrocellulose), followed by a hybridisation step, and a detection step. Southern blotting is used to identify a complementary DNA sequence; northern blotting is used to identify a complementary RNA
20 sequence. Dot blotting and slot blotting can be used to identify complementary DNA/DNA, DNA/RNA or RNA/RNA polynucleotide sequences. Such techniques are well known by those skilled in the art, and have been described in Ausubel *et al.* (1994-1998, *supra*) at pages 2.9.1 through 2.9.20.

According to such methods, Southern blotting involves separating DNA molecules
25 according to size by gel electrophoresis, transferring the size-separated DNA to a synthetic membrane, and hybridising the membrane-bound DNA to a complementary nucleotide sequence labelled radioactively, enzymatically or fluorochromatically. In dot blotting and slot blotting, DNA samples are directly applied to a synthetic membrane prior to hybridisation as above.

An alternative blotting step is used when identifying complementary polynucleotides in a
30 cDNA or genomic DNA library, such as through the process of plaque or colony hybridisation. A typical example of this procedure is described in Sambrook *et al.* ("Molecular Cloning. A Laboratory Manual", Cold Spring Harbour Press, 1989) Chapters 8-12.

Typically, the following general procedure can be used to determine hybridisation conditions. Polynucleotides are blotted/transferred to a synthetic membrane, as described above. A

reference polynucleotide such as a polynucleotide of the invention is labelled as described above, and the ability of this labelled polynucleotide to hybridise with an immobilised polynucleotide is analysed.

A skilled addressee will recognise that a number of factors influence hybridisation. The specific activity of radioactively labelled polynucleotide sequence should typically be greater than or equal to about 10^8 dpm/mg to provide a detectable signal. A radiolabelled nucleotide sequence of specific activity 10^8 to 10^9 dpm/mg can detect approximately 0.5 pg of DNA. It is well known in the art that sufficient DNA must be immobilised on the membrane to permit detection. It is desirable to have excess immobilised DNA, usually 10 μ g. Adding an inert polymer such as 10% (w/v) dextran sulphate (MW 500,000) or polyethylene glycol 6000 during hybridisation can also increase the sensitivity of hybridisation (see Ausubel *supra* at 2.10.10).

To achieve meaningful results from hybridisation between a polynucleotide immobilised on a membrane and a labelled polynucleotide, a sufficient amount of the labelled polynucleotide must be hybridised to the immobilized polynucleotide following washing. Washing ensures that the labelled polynucleotide is hybridised only to the immobilized polynucleotide with a desired degree of complementarity to the labelled polynucleotide.

It will be understood that polynucleotide variants according to the invention will hybridise to a reference polynucleotide under at least low stringency conditions. Reference herein to low stringency conditions include and encompass from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridisation at 42° C, and at least about 1 M to at least about 2 M salt for washing at 42° C. Low stringency conditions also may include 1% Bovine Serum Albumin (BSA), 1 mM EDTA, 0.5 M NaHPO₄ (pH 7.2), 7% SDS for hybridisation at 65° C, and (i) 2xSSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO₄ (pH 7.2), 5% SDS for washing at room temperature.

Suitably, the polynucleotide variants hybridise to a reference polynucleotide under at least medium stringency conditions. Medium stringency conditions include and encompass from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridisation at 42° C, and at least about 0.5 M to at least about 0.9 M salt for washing at 42° C. Medium stringency conditions also may include 1% Bovine Serum Albumin (BSA), 1 mM EDTA, 0.5 M NaHPO₄ (pH 7.2), 7% SDS for hybridisation at 65° C, and (i) 2 x SSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO₄ (pH 7.2), 5% SDS for washing at 42° C.

Desirably, the polynucleotide variants hybridise to a reference polynucleotide under high stringency conditions. High stringency conditions include and encompass from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 0.15 M

salt for hybridisation at 42° C, and at least about 0.01 M to at least about 0.15 M salt for washing at 42° C. High stringency conditions also may include 1% BSA, 1 mM EDTA, 0.5 M NaHPO₄ (pH 7.2), 7% SDS for hybridisation at 65° C, and (i) 0.2 x SSC, 0.1% SDS; or (ii) 0.5% BSA, 1mM EDTA, 40 mM NaHPO₄ (pH 7.2), 1% SDS for washing at a temperature in excess of 65° C.

5 Other stringent conditions are well known in the art. A skilled addressee will recognise that various factors can be manipulated to optimise the specificity of the hybridisation. Optimisation of the stringency of the final washes can serve to ensure a high degree of hybridisation. For detailed examples, see Ausubel *et al.*, *supra* at pages 2.10.1 to 2.10.16 and Sambrook *et al.* (1989, *supra*) at sections 1.101 to 1.104.

10 While stringent washes are typically carried out at temperatures from about 42° C to 68° C, one skilled in the art will appreciate that other temperatures may be suitable for stringent conditions. Maximum hybridisation typically occurs at about 20° C to 25° C below the T_m for formation of a DNA-DNA hybrid. It is well known in the art that the T_m is the melting temperature, or temperature at which two complementary polynucleotide sequences dissociate. Methods for
15 estimating T_m are well known in the art (see Ausubel *et al.*, *supra* at page 2.10.8).

In general, washing is carried out at $T = 69.3 + 0.41 (G + C) \% - 12^{\circ} \text{C}$. However, the T_m of a duplex DNA decreases by 1° C with every increase of 1% in the number of mismatched base pairs.

In an exemplary hybridisation procedure, a membrane (e.g., a nitrocellulose membrane or
20 a nylon membrane) containing immobilised DNA is hybridised overnight at 42° C in a hybridisation buffer (50% deionised formamide, 5xSSC, 5x Denhardt's solution (0.1% ficoll, 0.1% polyvinylpyrrolidone and 0.1% bovine serum albumin), 0.1% SDS and 200 mg/mL denatured salmon sperm DNA) containing labelled probe. The membrane is then subjected to two sequential medium stringency washes (i.e., 2xSSC/0.1% SDS for 15 min at 45° C, followed by 2xSSC/0.1%
25 SDS for 15 min at 50° C), followed by two sequential high stringency washes (i.e., 0.2xSSC/0.1% SDS for 12 min at 55° C followed by 0.2xSSC and 0.1%SDS solution for 12 min).

Methods for detecting a labelled polynucleotide hybridised to an immobilised polynucleotide are well known to practitioners in the art. Such methods include autoradiography, phosphorimaging, and chemiluminescent, fluorescent and colorimetric detection.

30 4. *Polypeptides encoded by the transcribed DNA sequence*

The TaBV genomic sequence comprises three ORFs, which encode the amino acid sequences set forth in SEQ ID NO:3, 4 and 5, respectively. Sequence comparisons between these ORFs and the ORFs of other badnaviruses including those of BSV, ComYMV, CSSV, CYMV, DaBV and SCBV, showed sequences identities ranging from 20-37% for ORF 1, 13-23% for ORF

2 and 30-37% for ORF 3. ORF 3 showed most similarity to that of other badnaviruses due to the presence of conserved motifs common to other badnaviruses including movement motifs, the RNA-binding domain (RB; C-X2-C-X4-H-X4-C), the second cysteine rich sequence (CYS) of unknown function, the aspartic protease motifs, reverse transcriptase domains and RNase H domains.

The amino acid sequences corresponding to these ORFs or portions thereof, are useful *inter alia* as targets in diagnostic applications for detecting badnavirus infections, especially TaBV infections and as immunogens for the preparation of antigen-binding molecules that are interactive with amino acid sequences encoded by those ORFs. Useful portions, which are contemplated by the present invention, are at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 amino acid residues in length.

5. Polypeptide variants

The invention also contemplates polypeptide variants of the polypeptides encoded by the TaBV ORFs described above. In general, these polypeptide variants will comprise regions that show preferably at least 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity to any one of the sequences set forth in SEQ ID NO:3, 4 and 5. It is preferred that variants display at least 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity to the sequence set forth in any one of SEQ ID NO:3, 4 or 5.

6. Promoter sequences of the invention

6.1 Promoter region of transcribed DNA sequence

The invention also provides an isolated promoter, located in the UTR between the end of ORF 3 and the start of ORF 1, which extends to include a tRNA^{met}-binding site at positions 1-12. In particular, an isolated polynucleotide comprising a constitutive promoter sequence for expression of chimeric or heterologous genes in plants, especially monocotyledonous plants, is provided and is set forth in SEQ ID NO:6. This promoter sequence is also referred to hereinafter as the TaBV promoter.

The invention also contemplates biologically active portions of SEQ ID NO:6 representative examples of which include the polynucleotide set forth in any one of SEQ ID NO:7, 8 and 9 as well as polynucleotide sequence variants thereof. Those of skill in the art will understand

that a biologically active portion or fragment of a promoter sequence, when fused to a particular gene and introduced into a plant cell, causes expression of the gene at a level higher than is possible in the absence of such fragment. One or more biologically active fragments may be included in a promoter according to the present invention, for instance one or more motifs may be coupled to a "minimal" promoter. Such motifs may confer TaBV promoter function on a promoter, such as suitability for enhanced performance in monocotyledonous plants and especially in non-graminaceous monocotyledonous plants such as, but not limited to, *Musaceae* (*Musa* and *Ensete*), taro, ginger, onions, garlic, pineapple, bromeliaeds, palms, orchids, lilies, irises and the like.

The activity of a promoter can be determined by methods well known in the art. For example, the level of promoter activity is quantifiable by assessment of the amount of mRNA produced by transcription from the promoter or by assessment of the amount of protein product produced by translation of mRNA produced by transcription from the promoter. The amount of a specific mRNA present in an expression system may be determined for example using specific oligonucleotides which are able to hybridise with the mRNA and which are labelled or may be used in a specific amplification reaction such as PCR. Use of a reporter gene facilitates determination of promoter activity by reference to protein production. Non-limiting methods for assessing promoter activity are disclosed by Medberry *et al.* (1992, *Plant Cell* 4:185; 1993, *The Plant J.* 3:619), Sambrook *et al.* (1989, *supra*) and McPherson *et al.* (U.S. Patent No. 5,164,316).

6.2 Promoter variants

Promoter variants that are substantially complementary to a reference promoter of the invention may be obtained by procedures outlined in Section 3. In general, these promoter variants will comprise regions that show identity values as described in Section 3. What constitutes suitable variants may be determined by conventional techniques. For example, polynucleotides according to SEQ ID NO:6, 7, 8 and 9 can be mutated using random mutagenesis (e.g., transposon mutagenesis), oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis and cassette mutagenesis of an earlier prepared variant or non-variant version of an isolated natural promoter according to the invention.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing nucleotide substitution variants of a promoter of the invention. This technique is well known in the art as, for example, described by Adelman *et al.* (1983, *DNA* 2:183). Briefly, promoter DNA is altered by hybridising an oligonucleotide encoding the desired mutation to a template DNA, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the promoter of interest. After hybridisation, a DNA polymerase is used to synthesise an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the promoter of interest.

Generally, oligonucleotides of at least 20 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridise properly to the single-stranded DNA template molecule.

5 The DNA template can be generated by those vectors that are either derived from bacteriophage M13 vectors, or those vectors that contain a single-stranded phage origin of replication as described by Viera *et al.* (1987, *Methods Enzymol.* 153:3). Thus, the DNA that is to be mutated may be inserted into one of the vectors to generate single-stranded template. Production of single-stranded template is described, for example, in Sections 4.21-4.41 of Sambrook *et al.*
10 (1989, *supra*).

Alternatively, the single-stranded template may be generated by denaturing double-stranded plasmid (or other DNA) using standard techniques.

For alteration of the native DNA sequence, the oligonucleotide is hybridised to the single-stranded template under suitable hybridisation conditions. A DNA polymerising enzyme, usually
15 the Klenow fragment of DNA polymerase I, is then added to synthesise the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of the promoter under test, and the other strand (the original template) encodes the native unaltered sequence of the promoter under test. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote
20 such as *E. coli*. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer having a detectable label to identify the bacterial colonies having the mutated DNA. The resultant mutated DNA fragments are then cloned into suitable expression hosts such as *E. coli* using conventional technology and clones that retain the desired promoter activity are detected. Where the clones have been derived using random mutagenesis techniques, positive
25 clones would have to be sequenced in order to detect the mutation.

Alternatively, linker-scanning mutagenesis of DNA may be used to introduce clusters of point mutations throughout a sequence of interest that has been cloned into a plasmid vector. For example, reference may be made to Ausubel *et al.*, *supra*, (in particular, Chapter 8.4) which describes a first protocol that uses complementary oligonucleotides and requires a unique
30 restriction site adjacent to the region that is to be mutagenised. A nested series of deletion mutations is first generated in the region. A pair of complementary oligonucleotides is synthesised to fill in the gap in the sequence of interest between the linker at the deletion endpoint and the nearby restriction site. The linker sequence actually provides the desired clusters of point mutations as it is moved or "scanned" across the region by its position at the varied endpoints of the deletion
35 mutation series. An alternate protocol is also described by Ausubel *et al.*, *supra*, which makes use

of site directed mutagenesis procedures to introduce small clusters of point mutations throughout the target region. Briefly, mutations are introduced into a sequence by annealing a synthetic oligonucleotide containing one or more mismatches to the sequence of interest cloned into a single-stranded M13 vector. This template is grown in an *Escherichia coli dut ung* strain, which allows the incorporation of uracil into the template strand. The oligonucleotide is annealed to the template and extended with T4 DNA polymerase to create a double-stranded heteroduplex. Finally, the heteroduplex is introduced into a wild-type *E. coli* strain, which will prevent replication of the template strand due to the presence of apurinic sites (generated where uracil is incorporated), thereby resulting in plaques containing only mutated DNA.

Region-specific mutagenesis and directed mutagenesis using PCR may also be employed to construct promoter variants according to the invention. In this regard, reference may be made, for example, to Ausubel *et al.*, *supra*, in particular Chapters 8.2A and 8.5.

7. Chimeric DNA construct

A promoter or biologically active variant or fragment according to the invention can be fused to a foreign or endogenous DNA sequence to create a chimeric DNA construct for introduction into plants.

7.1 3' Non-translated region

In some embodiments, the chimeric DNA construct of the present invention is in the form of an expression cassette designed for genetic transformation of plants. In this embodiment, the chimeric DNA construct suitably comprises a 3' non-translated sequence that is operably linked to the foreign or endogenous DNA sequence and that functions in plant cells to terminate transcription and/or to cause addition of a polyadenylated nucleotide sequence to the 3' end of a RNA sequence transcribed from the foreign or endogenous DNA sequence. Thus, a 3' non-translated sequence refers to that portion of a gene comprising a DNA segment that contains a transcriptional termination signal and/or a polyadenylation signal and any other regulatory signals (e.g., translational termination signals) capable of effecting mRNA processing or gene expression. The polyadenylation signal is characterised by effecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. Polyadenylation signals are commonly recognised by the presence of homology to the canonical form 5' AATAAA-3' although variations are not uncommon.

The 3' non-translated regulatory DNA sequence preferably includes from about 50 to 1,000 nucleotide base pairs and contains plant transcriptional and translational termination sequences. Examples of suitable 3' non-translated sequences are the 3' transcribed non-translated regions containing a polyadenylation signal from the nopaline synthase (*nos*) gene of *Agrobacterium tumefaciens* (Bevan *et al.*, 1983, *Nucl. Acid Res.*, 11:369) and the terminator for the

T7 transcript from the octopine synthase gene of *Agrobacterium tumefaciens*. Alternatively, suitable 3' non-translated sequences may be derived from plant genes such as the 3' end of the protease inhibitor I or II genes from potato or tomato, the soybean storage protein genes and the pea E9 small subunit of the ribulose-1,5-bisphosphate carboxylase (ssRUBISCO) gene, although other 3' elements known to those of skill in the art can also be employed. Alternatively, 3' non-translated regulatory sequences can be obtained *de novo* as, for example, described by An (1987, *Methods in Enzymology*, 153:292).

7.2 Optional sequences

The chimeric DNA construct of the present invention can further include enhancers, either translation or transcription enhancers, as may be required. These enhancer elements are well known to persons skilled in the art, and can include the ATG initiation codon and adjacent sequences. The initiation codon must be in phase with the reading frame of the coding sequence relating to the foreign or endogenous DNA sequence to ensure translation of the entire sequence. The translation control signals and initiation codons can be of a variety of origins, both natural and synthetic. Translational initiation regions may be provided from the source of the transcriptional initiation region, or from the foreign or endogenous DNA sequence. The sequence can also be derived from the source of the promoter selected to drive transcription, and can be specifically modified so as to increase translation of the mRNA.

Examples of transcriptional enhancers include, but are not restricted to, elements from the CaMV 35S promoter and octopine synthase genes as for example described by Last *et al.* (U.S. Patent No. 5,290,924). It is proposed that the use of an enhancer element such as the *ocs* element, and particularly multiple copies of the element, will act to increase the level of transcription from adjacent promoters when applied in the context of plant transformation. As the DNA sequence inserted between the transcription initiation site and the start of the coding sequence, i.e., the untranslated leader sequence, can influence gene expression, one can also employ a particular leader sequence. Preferred leader sequences include those that comprise sequences selected to direct optimum expression of the foreign or endogenous DNA sequence. For example, such leader sequences include a preferred consensus sequence which can increase or maintain mRNA stability and prevent inappropriate initiation of translation as for example described by Joshi (1987, *Nucl. Acid Res.*, 15:6643). However, other leader sequences, e.g., the leader sequence of RTBV, have a high degree of secondary structure that is expected to decrease mRNA stability and/or decrease translation of the mRNA. Thus, leader sequences (i) that do not have a high degree of secondary structure, (ii) that have a high degree of secondary structure where the secondary structure does not inhibit mRNA stability and/or decrease translation, or (iii) that are derived from genes that are highly expressed in plants, will be most preferred.

Regulatory elements such as the sucrose synthase intron as, for example, described by Vasil *et al.* (1989, *Plant Physiol.*, 91:5175), the Adh intron I as, for example, described by Callis *et al.* (1987, *Genes Develop.*, II), or the TMV omega element as, for example, described by Gallie *et al.* (1989, *The Plant Cell*, 1:301) can also be included where desired. Other such regulatory elements useful in the practice of the invention are known to those of skill in the art.

Additionally, targeting sequences may be employed to target a protein product of the foreign or endogenous DNA sequence to an intracellular compartment within plant cells or to the extracellular environment. For example, a DNA sequence encoding a transit or signal peptide sequence may be operably linked to a sequence encoding a desired protein such that, when translated, the transit or signal peptide can transport the protein to a particular intracellular or extracellular destination, respectively, and can then be post-translationally removed. Transit or signal peptides act by facilitating the transport of proteins through intracellular membranes, e.g., vacuole, vesicle, plastid and mitochondrial membranes, whereas signal peptides direct proteins through the extracellular membrane. For example, the transit or signal peptide can direct a desired protein to a particular organelle such as a plastid (e.g., a chloroplast), rather than to the cytoplasm. Thus, the chimeric DNA construct can further comprise a plastid transit peptide encoding DNA sequence operably linked between a promoter or biologically active variant or fragment according to the invention and the foreign or endogenous DNA sequence. For example, reference may be made to Heijne *et al.* (1989, *Eur. J. Biochem.*, 180:535) and Keegstra *et al.* (1989, *Ann. Rev. Plant Physiol. Plant Mol. Biol.*, 40:471).

A chimeric DNA construct can also be introduced into a vector, such as a plasmid. Plasmid vectors include additional DNA sequences that provide for easy selection, amplification, and transformation of the expression cassette in prokaryotic and eukaryotic cells, e.g., pUC-derived vectors, pSK-derived vectors, pGEM-derived vectors, pSP-derived vectors, or pBS-derived vectors. Additional DNA sequences include origins of replication to provide for autonomous replication of the vector, selectable marker genes, preferably encoding antibiotic or herbicide resistance, unique multiple cloning sites providing for multiple sites to insert DNA sequences or genes encoded in the chimeric DNA construct, and sequences that enhance transformation of prokaryotic and eukaryotic cells.

The vector suitably contains an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell. The vector may be integrated into the host cell genome when introduced into a host cell. For integration, the vector may rely on the foreign or endogenous DNA sequence or any other element of the vector for stable integration of the vector into the genome by homologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for

directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location in the chromosome. To increase the likelihood of integration at a precise location, the integrational elements should desirably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, usually 400 to 1,500 base pairs, and more usually 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAM.beta.1 permitting replication in *Bacillus*. The origin of replication may be one having a mutation to make its function temperature-sensitive in a *Bacillus* cell (see, e.g., Ehrlich, 1978, *Proc. Natl. Acad. Sci. USA* 75:1433).

7.3 Marker genes

To facilitate identification of transformants, the chimeric DNA construct desirably comprises a selectable or screenable marker gene as, or in addition to, the expressible foreign or endogenous DNA sequence. The actual choice of a marker is not crucial as long as it is functional in combination with the plant cells of choice. The marker gene and the foreign or endogenous DNA sequence of interest do not have to be linked, since co-transformation of unlinked genes as, for example, described in U.S. Pat. No. 4,399,216 is also an efficient process in plant transformation.

Included within the terms selectable or screenable marker genes are genes that encode a "secretable marker" whose secretion can be detected as a means of identifying or selecting for transformed cells. Examples include markers that encode a secretable antigen that can be identified by antibody interaction, or secretable enzymes that can be detected by their catalytic activity. Secretable proteins include, but are not restricted to, proteins that are inserted or trapped in the cell wall (e.g., proteins that include a leader sequence such as that found in the expression unit of extensin or tobacco PR-S); small, diffusible proteins detectable, e.g. by ELISA; and small active enzymes detectable in extracellular solution (e.g., α -amylase, β -lactamase, phosphinothricin acetyltransferase).

7.4 Selectable markers

Examples of bacterial selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, or markers that confer antibiotic resistance such as ampicillin, kanamycin, erythromycin, chloramphenicol or tetracycline resistance. Exemplary selectable markers for selection of plant transformants include, but are not limited to, a *hyg* gene which encodes hygromycin B resistance; a neomycin phosphotransferase (*neo*) gene conferring resistance to kanamycin, paromomycin, G418 and the like as, for example, described by Potrykus *et al.* (1985, *Mol. Gen. Genet.* 199:183); a glutathione-S-transferase gene from rat liver conferring resistance to glutathione derived herbicides as, for example, described in EP-A 256 223; a glutamine synthetase gene conferring, upon overexpression, resistance to glutamine synthetase inhibitors such as phosphinothricin as, for example, described WO87/05327, an acetyl transferase gene from *Streptomyces viridochromogenes* conferring resistance to the selective agent phosphinothricin as, for example, described in EP-A 275 957, a gene encoding a 5-enolshikimate-3-phosphate synthase (EPSPS) conferring tolerance to N-phosphonomethylglycine as, for example, described by Hinchee *et al.* (1988, *Biotech.*, 6:915), a *bar* gene conferring resistance against bialaphos as, for example, described in WO91/02071; a nitrilase gene such as *bxn* from *Klebsiella ozaenae* which confers resistance to bromoxynil (Stalker *et al.*, 1988, *Science*, 242:419); a dihydrofolate reductase (DHFR) gene conferring resistance to methotrexate (Thillet *et al.*, 1988, *J. Biol. Chem.*, 263:12500); a mutant acetolactate synthase gene (ALS), which confers resistance to imidazolinone, sulfonylurea or other ALS-inhibiting chemicals (EP-A-154 204); a mutated anthranilate synthase gene that confers resistance to 5-methyl tryptophan; or a dalapon dehalogenase gene that confers resistance to the herbicide.

7.5 Screenable markers

Preferred screenable markers include, but are not limited to, a *uidA* gene encoding a β -glucuronidase (GUS) enzyme for which various chromogenic substrates are known; a β -galactosidase gene encoding an enzyme for which chromogenic substrates are known; an aequorin gene (Prasher *et al.*, 1985, *Biochem. Biophys. Res. Comm.*, 126:1259), which may be employed in calcium-sensitive bioluminescence detection; a green fluorescent protein gene (Niedz *et al.*, 1995 *Plant Cell Reports*, 14:403); a luciferase (*luc*) gene (Ow *et al.*, 1986, *Science*, 234:856), which allows for bioluminescence detection; a β -lactamase gene (Sutcliffe, 1978, *Proc. Natl. Acad. Sci. USA* 75:3737), which encodes an enzyme for which various chromogenic substrates are known (e.g., PADAC, a chromogenic cephalosporin); an R-locus gene, encoding a product that regulates the production of anthocyanin pigments (red colour) in plant tissues (Dellaporta *et al.*, 1988, in *Chromosome Structure and Function*, pp. 263-282); an α -amylase gene (Ikuta *et al.*, 1990, *Biotech.*, 8:241); a tyrosinase gene (Katz *et al.*, 1983, *J. Gen. Microbiol.*, 129:2703) which encodes

an enzyme capable of oxidizing tyrosine to dopa and dopaquinone which in turn condenses to form the easily detectable compound melanin; or a *xylE* gene (Zukowsky *et al.*, 1983, *Proc. Natl. Acad. Sci. USA* 80:1101), which encodes a catechol dioxygenase that can convert chromogenic catechols.

8. *Uses of the promoter of the invention*

5 The isolated promoter sequence may be used, *inter alia*, to drive expression of a foreign or endogenous DNA sequence. The foreign or endogenous DNA sequence may comprise a region transcribed into an RNA molecule that modulates the expression of a corresponding target gene. Such modulation of expression may be achieved, for example, by antisense technology, ribozyme technology and co-suppression or homology-dependent gene silencing, as is known in the art.
10 Accordingly, the transcript may comprise an antisense RNA molecule, or a ribozyme or other transcript (such as inverted repeats and dsRNA, as mentioned, for instance, below) aimed at downregulation of expression of the corresponding target gene.

 Thus, in some embodiments, the transcript is an antisense RNA molecule that directly blocks the translation of mRNA transcribed from a target gene by binding to the mRNA and
15 preventing protein translation. When employed, antisense RNAs should be at least about 10-20 nucleotides or greater in length, and be at least about 75% complementary to their target genes or gene transcripts such that expression of the targeted homologous sequence is precluded.

 In other embodiments, the transcript is a ribozyme that functions to inhibit the translation of a target gene mRNA. Ribozymes are enzymatic RNA molecules capable of catalysing the
20 specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridisation of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyse endonucleolytic cleavage of target gene RNA sequences. Specific ribozyme cleavage sites within any potential RNA target are
25 initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. When employed, ribozymes may be selected from the group
30 consisting of hammerhead ribozymes, axehead ribozymes, newt satellite ribozymes, Tetrahymena ribozymes and RNase P, and are designed according to methods known in the art based on the sequence of the target gene (for instance, see U.S. Pat. No. 5,741,679). The suitability of candidate targets may also be evaluated by testing their accessibility to hybridisation with complementary oligonucleotides, using ribonuclease protection assays.

In other embodiments, the transcript is an RNA molecule that mediates RNA interference (RNAi) of a target gene or gene transcript. RNAi refers to interference with or destruction of the product of a target gene by introducing a single stranded, and typically a double stranded RNA (dsRNA), which is homologous to the transcript of a target gene. Thus, in some embodiments, dsRNA *per se* and especially dsRNA-producing constructs corresponding to at least a portion of a target gene may be used to decrease its level and/or functional activity. RNAi-mediated inhibition of gene expression may be accomplished using any of the techniques reported in the art, for instance by transfecting a nucleic acid construct encoding a stem-loop or hairpin RNA structure into the genome of the target cell, or by expressing a transfected nucleic acid construct having homology for a target gene from between convergent promoters, or as a head to head or tail to tail duplication from behind a single promoter. Any similar construct may be used so long as it produces a single RNA having the ability to fold back on itself and produce a dsRNA, or so long as it produces two separate RNA transcripts which then anneal to form a dsRNA having homology to a target gene.

Absolute homology is not required for RNAi, with a lower threshold being described at about 85% homology for a dsRNA of about 200 base pairs (Plasterk and Ketting, 2000, *Current Opinion in Genetics and Dev.* 10: 562-67). Therefore, depending on the length of the dsRNA, the RNAi-encoding nucleic acids can vary in the level of homology they contain toward the target gene transcript, *i.e.*, with dsRNAs of 100 to 200 base pairs having at least about 85% homology with the target gene, and longer dsRNAs, *i.e.*, 300 to 100 base pairs, having at least about 75% homology to the target gene. RNA-encoding constructs that express a single RNA transcript designed to anneal to a separately expressed RNA, or single constructs expressing separate transcripts from convergent promoters, are preferably at least about 100 nucleotides in length. RNA-encoding constructs that express a single RNA designed to form a dsRNA *via* internal folding are preferably at least about 200 nucleotides in length.

The promoter used to express the dsRNA-forming construct may be any type of promoter if the resulting dsRNA is specific for a gene product in the cell lineage targeted for destruction. Alternatively, the promoter may be lineage specific in that it is only expressed in cells of a particular development lineage. This might be advantageous where some overlap in homology is observed with a gene that is expressed in a non-targeted cell lineage. The promoter may also be inducible by externally controlled factors, or by intracellular environmental factors.

In another embodiment, RNA molecules of about 21 to about 23 nucleotides, which direct cleavage of specific mRNA to which they correspond, as for example described by Tuschl *et al.* in U.S. Patent Application No. 20020086356, can be utilised for mediating RNAi. Such 21-23 nt RNA molecules can comprise a 3' hydroxyl group, can be single-stranded or double stranded (as

two 21-23 nt RNAs) wherein the dsRNA molecules can be blunt ended or comprise overhanging ends (e.g., 5', 3').

In other embodiments, the foreign or endogenous DNA sequence encodes: a detectable or measurable product, e.g. β -glucuronidase or luciferase; a selectable product, e.g., neomycin phosphotransferase (nptII) conferring resistance to aminoglycosidic antibiotics such as geneticin and paromomycin; a product conferring herbicide tolerance, e.g. glyphosate resistance or glufosinate resistance; a product affecting starch biosynthesis or modification e.g. starch branching enzyme, starch synthases, ADP-glucose pyrophosphorylase; a product involved in fatty acid biosynthesis, e.g. desaturase or hydroxylase; a product conferring insect resistance, e.g. crystal toxin protein of *Bacillus thuringiensis*; a product conferring viral resistance, e.g. viral coat protein; a product conferring fungal resistance, e.g. chitinase, β -1,3-glucanase or phytoalexins; a product altering sucrose metabolism, e.g. invertase or sucrose synthase; a gene encoding valuable pharmaceuticals, e.g. antibiotics, secondary metabolites, pharmaceutical peptides or vaccines.

The foreign or endogenous DNA sequence includes, but is not limited to, DNA from plant genes, and non-plant genes such as those from bacteria, yeasts, animals or viruses. Moreover, it is within the scope of the invention to isolate a foreign or endogenous DNA sequence from a given plant genotype, and to subsequently introduce multiple copies of that sequence into the same genotype, e.g., to enhance production of a given gene product. The introduced DNA can include modified genes, portions of genes, or chimeric genes, including genes from the same or different plant genotype.

Exemplary agronomic properties encoded by the foreign or endogenous DNA sequence include, but are not limited to: traits that are beneficial to the grower such as resistance to water deficit, pest resistance or tolerance, herbicide resistance or tolerance, disease resistance or tolerance (e.g., resistance to viruses or fungal pathogens), stress tolerance (increased salt tolerance) and improved food content or increased yields; traits that are beneficial to the consumer of the horticultural produce harvested from the plant such as improved nutritive content in human food or animal feed; or beneficial to the food processor such as improved processing traits. In such uses, the transgenic plants containing the promoter of the invention are generally grown for the use of their grain, fruit and other plant parts, including stalks, husks, vegetative parts, and the like in human or animal foods including use as part of animal silage or for ornamental purposes. Often, chemical constituents of crops are extracted for foods or industrial use and transgenic plants may be created which have enhanced or modified levels of such components.

The isolated promoter sequence of the invention may also find use in the commercial manufacture of proteins or other compounds, where the compound of interest is extracted or purified from plant parts, seeds, and the like. Such proteins or compounds include, but are not

limited to, immunogenic molecules for use in vaccines, cytokines and hormones. Cells or tissue from the plants may also be cultured, grown *in vitro*, or fermented to manufacture such molecules.

The transgenic plants containing the isolated promoter sequence of the invention may also be used in commercial breeding programs, or may be crossed or bred to plants of related crop species. Improvements encoded by the foreign or endogenous DNA sequence may be transferred, 5 e.g., from cells of one plant species to cells of another plant species, e.g., by protoplast fusion.

The transgenic plants containing the isolated promoter sequence of the invention may have many uses in research or breeding, including creation of new mutant plants through insertional mutagenesis, in order to identify beneficial mutants that might later be created by 10 traditional mutation and selection. An example would be the introduction of a recombinant DNA sequence encoding a transposable element that may be used for generating genetic variation or the introduction of unique "signature sequences" or other marker sequences which can be used to identify proprietary lines or varieties.

9. *Introduction of chimeric construct into plant cells*

15 Generally, the present invention employs recipient plant cells that are susceptible to transformation and subsequent regeneration into stably transformed, fertile plants. For monocot transformation for example, immature embryos, meristematic tissue, gametic tissue, embryogenic suspension cultures or embryogenic callus tissue can be employed as a source of recipient cells which is useful in the practice of the invention. For dicot transformation, organ and tissue cultures 20 can be employed as a source of recipient cells. Thus, tissues, e.g., leaves, seed and roots, of dicots can provide a source of recipient cells useful in the practice of the invention.

Cultured susceptible recipient cells are preferably grown on solid supports. Nutrients are provided to the cultures in the form of media and the environmental conditions for the cultures are controlled. Media and environmental conditions which support the growth of regenerable plant 25 cultures are well known to the art.

A number of techniques are available for the introduction of DNA into a recipient plant cell. There are many plant transformation techniques well known to workers in the art, and new techniques are continually becoming known. The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and 30 preference of the person practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce a chimeric DNA construct into plant cells is not essential to or a limitation of the invention, provided it achieves an acceptable level of nucleic acid transfer. Guidance in the practical implementation of

transformation systems for plant improvement is provided, for example, by Birch (1997, *Annu. Rev. Plant Physiol. Plant Molec. Biol.* 48: 297-326).

In principle both dicotyledonous and monocotyledonous plants that are amenable to transformation, can be modified by introducing a chimeric DNA construct according to the invention into a recipient cell and growing a new plant that harbours and expresses the foreign or endogenous DNA sequence.

Introduction and expression of foreign or chimeric DNA sequences in dicotyledonous (broad-leafed) plants such as tobacco, potato and alfalfa has been shown to be possible using the T-DNA of the tumour-inducing (Ti) plasmid of *Agrobacterium tumefaciens* (See, for example, Umbeck, U.S. Patent No. 5,004,863, and International application PCT/US93/02480). A construct of the invention may be introduced into a plant cell utilising *A. tumefaciens* containing the Ti plasmid. In using an *A. tumefaciens* culture as a transformation vehicle, it is most advantageous to use a non-oncogenic strain of the *Agrobacterium* as the vector carrier so that normal non-oncogenic differentiation of the transformed tissues is possible. It is preferred that the *Agrobacterium* harbours a binary Ti plasmid system. Such a binary system comprises (1) a first Ti plasmid having a virulence region essential for the introduction of transfer DNA (T-DNA) into plants, and (2) a chimeric plasmid. The chimeric plasmid contains at least one border region of the T-DNA region of a wild-type Ti plasmid flanking the nucleic acid to be transferred. Binary Ti plasmid systems have been shown effective to transform plant cells as, for example, described by De Framond (1983, *Biotechnology*, 1:262) and Hoekema *et al.* (1983, *Nature*, 303:179). Such a binary system is preferred *inter alia* because it does not require integration into the Ti plasmid in *Agrobacterium*.

Methods involving the use of *Agrobacterium* include, but are not limited to: (a) co-cultivation of *Agrobacterium* with cultured isolated protoplasts; (b) transformation of plant cells or tissues with *Agrobacterium*; or (c) transformation of seeds, apices or meristems with *Agrobacterium*.

Recently, rice and corn, which are monocots, have been shown to be susceptible to transformation by *Agrobacterium* as well. Garlic and onion, which are also monocots, have been successfully transformed and regenerated by *Agrobacterium* mediated gene transfer (Kondo *et al.*, 2000, *Plant Cell Reports*, 19(10): 989-993; Eady *et al.*, 2000, *Plant Cell Reports*, 19(4): 376-381). However, many other important monocot crop plants, including oats, sorghum, millet, and rye, have not yet been successfully transformed using *Agrobacterium*-mediated transformation. The Ti plasmid, however, may be manipulated in the future to act as a vector for these other monocot plants. Additionally, using the Ti plasmid as a model system, it may be possible to artificially construct transformation vectors for these plants. Ti plasmids might also be introduced into monocot plants by artificial methods such as microinjection, or fusion between monocot

protoplasts and bacterial spheroplasts containing the T-region, which can then be integrated into the plant nuclear DNA.

In addition, gene transfer can be accomplished by *in situ* transformation by *Agrobacterium*, as described by Bechtold *et al.* (1993, *C.R. Acad. Sci. Paris*, 316:1194). This approach is based on the vacuum infiltration of a suspension of *Agrobacterium* cells.

Alternatively, foreign or chimeric nucleic acids may be introduced using root-inducing (Ri) plasmids of *Agrobacterium* as vectors.

Cauliflower mosaic virus (CaMV) may also be used as a vector for introducing of exogenous nucleic acids into plant cells (U.S. Pat. No. 4,407,956). CaMV DNA genome is inserted into a parent bacterial plasmid creating a recombinant DNA molecule that can be propagated in bacteria. After cloning, the recombinant plasmid again may be cloned and further modified by introduction of the desired nucleic acid sequence. The modified viral portion of the recombinant plasmid is then excised from the parent bacterial plasmid, and used to inoculate the plant cells or plants.

Foreign or chimeric nucleic acids can also be introduced into plant cells by electroporation as, for example, described by Fromm *et al.* (1985, *Proc. Natl. Acad. Sci., U.S.A.*, 82:5824) and Shimamoto *et al.* (1989, *Nature* 338:274-276). In this technique, plant protoplasts are electroporated in the presence of vectors or nucleic acids containing the relevant nucleic acid sequences. Electrical impulses of high field strength reversibly permeabilise membranes allowing the introduction of nucleic acids. Electroporated plant protoplasts reform the cell wall, divide and form a plant callus.

Another method for introducing foreign or chimeric nucleic acids into a plant cell is high velocity ballistic penetration by small particles (also known as particle bombardment or microprojectile bombardment) with the nucleic acid to be introduced contained either within the matrix of small beads or particles, or on the surface thereof as, for example described by Klein *et al.* (1987, *Nature* 327:70). Although typically only a single introduction of a new nucleic acid sequence is required, this method particularly provides for multiple introductions.

Alternatively, foreign or chimeric nucleic acids can be introduced into a plant cell by contacting the plant cell using mechanical or chemical means. For example, a nucleic acid can be mechanically transferred by microinjection directly into plant cells by use of micropipettes. Alternatively, a nucleic acid may be transferred into the plant cell by using polyethylene glycol which forms a precipitation complex with genetic material that is taken up by the cell.

There are a variety of methods known currently for transformation of monocotyledonous plants. Presently, preferred methods for transformation of monocots are microprojectile

bombardment of explants or suspension cells, and direct DNA uptake or electroporation as, for example, described by Shimamoto *et al.* (1989, *supra*). Transgenic maize plants have been obtained by introducing the *Streptomyces hygroscopicus bar* gene into embryogenic cells of a maize suspension culture by microprojectile bombardment (Gordon-Kamm, 1990, *Plant Cell*, 2:603-618). The introduction of genetic material into aleurone protoplasts of other monocotyledonous crops such as wheat and barley has been reported (Lee, 1989, *Plant Mol. Biol.* 13:21-30). Wheat plants have been regenerated from embryogenic suspension culture by selecting only the aged compact and nodular embryogenic callus tissues for the establishment of the embryogenic suspension cultures (Vasil, 1990, *Bio/Technol.* 8:429-434). The combination with transformation systems for these crops enables the application of the present invention to monocots. These methods may also be applied for the transformation and regeneration of dicots. Transgenic sugarcane plants have been regenerated from embryogenic callus as, for example, described by Bower *et al.* (1996, *Molecular Breeding* 2:239-249).

Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, e.g., bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

10. Production and characterisation of differentiated transgenic plants

The methods used to regenerate transformed cells into differentiated plants are not critical to this invention, and any method suitable for a target plant can be employed. Normally, a plant cell is regenerated to obtain a whole plant following a transformation process.

Regeneration from protoplasts varies from species to species of plants, but generally a suspension of protoplasts is first made. In certain species, embryo formation can then be induced from the protoplast suspension, to the stage of ripening and germination as natural embryos. The culture media will generally contain various amino acids and hormones, necessary for growth and regeneration. Examples of hormones utilised include auxins and cytokinins. It is sometimes advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these variables are controlled, regeneration is reproducible. Regeneration also occurs from plant callus, explants, organs or parts. Transformation can be performed in the context of organ or plant part regeneration as, for example, described in *Methods in Enzymology*, Vol. 118 and Klee *et al.* (1987, *Annual Review of Plant Physiology*, 38:467). Utilising the leaf disk-transformation-regeneration method of Horsch *et al.* (1985, *Science*, 227:1229), disks are cultured on selective media, followed by shoot formation in about 2-4 weeks. Shoots that develop are excised from calli and transplanted to appropriate root-inducing selective medium. Rooted plantlets

are transplanted to soil as soon as possible after roots appear. The plantlets can be repotted as required, until maturity is reached.

In vegetatively propagated crops, the mature transgenic plants are propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants. Selection of
5 desirable transgenotes is made and new varieties are obtained and propagated vegetatively for commercial use.

In seed propagated crops, the mature transgenic plants can be self-crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the newly introduced foreign gene(s). These seeds can be grown to produce plants that would produce the selected phenotype,
10 e.g., early flowering.

The transgenic plants of the invention include, but are not limited to, a transgenic T0 or R0 plant, i.e., the first plant regenerated from transformed plant cells, a transgenic T1 or R1 plant, i.e., the first generation progeny plant, and progeny plants of further generations derived therefrom which comprise and express the chimeric DNA construct.

15 Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit, and the like are included in the invention, provided that these parts comprise cells that have been transformed as described. Progeny and variants, and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences.

20 It will be appreciated that the literature describes numerous techniques for regenerating specific plant types and more are continually becoming known. Those of ordinary skill in the art can refer to the literature for details and select suitable techniques without undue experimentation.

11. Characterisation

To confirm the presence of the foreign or endogenous DNA sequence in the regenerating
25 plants, a variety of assays may be performed. Such assays include, for example, "molecular biological" assays well known to those of skill in the art, such as Southern and Northern blotting and PCR. A protein expressed by the heterologous DNA may be analysed by high performance liquid chromatography or ELISA (e.g., nptII) as is well known in the art.

12. Diagnostic applications

30 The invention also extends to a method diagnosing a badnaviral infection of a plant, comprising detecting the presence in a cell or tissue of the plant of a nucleotide sequence that corresponds or is complementary to at least a portion of the sequence set forth in SEQ ID NO:1 or

2, or to a variant thereof, or an amino acid sequence that corresponds to at least a portion of the sequence set forth in SEQ ID NO:3, 4 or 5, or to a variant thereof.

12.1 Nucleic acid-based diagnostics

Nucleic acid used in polynucleotide-based assays can be isolated from cells contained in the biological sample obtained from a plant or plants part, according to standard methodologies (Sambrook, *et al.*, "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, 1989; Ausubel *et al.*, "Current Protocols in Molecular Biology", John Wiley & Sons Inc, 1994-1998). The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to convert the RNA to a complementary DNA. In one embodiment, the RNA is whole cell RNA; in another, it is poly-A RNA. In one embodiment, the nucleic acid is amplified by a nucleic acid amplification technique, as described for example in Section 3.

Depending on the format, the specific nucleic acid of interest is identified in the sample directly using amplification or with a second, known nucleic acid following amplification. Next, the identified product is detected. In certain applications, the detection may be performed by visual means (e.g., ethidium bromide staining of a gel). Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of radiolabel or fluorescent label or even *via* a system using electrical or thermal impulse signals (Affymax Technology; Bellus, 1994, *J Macromol. Sci. Pure, Appl. Chem.*, A31(1): 1355-1376).

Following detection, one may compare the results seen in a given plant with a control reaction or a statistically significant reference group of normal plants. In this way, it is possible to correlate the amount of product expressed by the virus with the progression or severity of the infection.

12.2 Protein-based diagnostics

12.2.1 Antigen-binding molecules

Antigen-binding molecules that are immuno-interactive with a target molecule of the present invention can be used in the detection a TaBV polypeptide of the invention or a variant thereof. Thus, the present invention contemplates antigen-binding molecules that interact, for example, with an amino acid sequence corresponding to the sequence set forth in SEQ ID NO:3, 4 or 5. Illustrative assay strategies which can be used to detect a target polypeptide of the invention include, but are not limited to, immunoassays (e.g., Western blot or ELISA) involving the binding of an antigen-binding molecule to the target polypeptide in the sample, and the detection of a complex, which comprises the antigen-binding molecule and the target polypeptide.

Any suitable technique for determining formation of an antigen-binding molecule-target antigen complex may be used. For example, an antigen-binding molecule according to the invention, having a reporter molecule associated therewith may be utilised in immunoassays. Such immunoassays include, but are not limited to, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs) and immunochromatographic techniques (ICTs), Western blotting which are well known those of skill in the art. For example, reference may be made to Coligan *et al.* (1994, *supra*) which discloses a variety of immunoassays that may be used in accordance with the present invention. Immunoassays may include competitive assays as understood in the art or as for example described *infra*. It will be understood that the present invention encompasses qualitative and quantitative immunoassays.

13. Identification of target molecule modulators

The invention also features a method of screening for an agent that modulates the expression of one or more of the TaBV open reading frames or variants thereof. The method comprises contacting a preparation comprising (i) at least a portion of the expression product or variant thereof, or (ii) at least a portion of a genetic sequence (e.g., a promoter), which regulates the expression of the open reading frame(s), in operable linkage with a reporter polynucleotide, with a test agent, and detecting a change in the level and/or functional activity of an expression product produced from (i) or (ii) relative to a normal or reference level and/or functional activity in the absence of said test agent.

Test agents contemplated by the present invention include agonists and antagonists of the ORFs and polypeptides described herein. Antagonists of include antisense molecules, ribozymes and co-suppression molecules as well as antibodies and inhibitor peptide fragments. Agonists include molecules which increase promoter activity or interfere with negative mechanisms.

Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 Dalton. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including, but not limited to: peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogues or combinations thereof.

Small (non-peptide) molecule modulators of are particularly preferred. In this regard, small molecules are particularly preferred because such molecules are more readily absorbed after oral administration, have fewer potential antigenic determinants, and/or are more likely to cross the cell membrane than larger, protein-based pharmaceuticals. Small organic molecules may also have the ability to gain entry into an appropriate cell and affect the expression of a gene (e.g., by interacting with the regulatory region or transcription factors involved in gene expression); or affect the activity of a gene by inhibiting or enhancing the binding of accessory molecules.

Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogues. Screening may also be directed to known pharmacologically active compounds and chemical analogues thereof.

Screening for modulatory agents according to the invention can be achieved by any suitable method. For example, the method may include contacting a cell in which a polynucleotide corresponding to a TaBV ORF is expressed with an agent suspected of having said modulatory activity and screening for the modulation of the level and/or functional activity of a protein encoded by the polynucleotide, or the modulation of the level of an expression product encoded by the polynucleotide, or the modulation of the activity or expression of a downstream cellular target of the protein or the expression product. Detecting such modulation can be achieved using techniques including, but not restricted to, ELISA, cell-based ELISA, filter-binding ELISA, inhibition ELISA, Western blots, immunoprecipitation, slot or dot blot assays, immunostaining, RIA, scintillation proximity assays, fluorescent immunoassays using antigen-binding molecule conjugates or antigen conjugates of fluorescent substances such as fluorescein or rhodamine, Ouchterlony double diffusion analysis, immunoassays employing an avidin-biotin or a streptavidin-biotin detection system, and nucleic acid detection assays including reverse transcriptase polymerase chain reaction (RT-PCR).

It will be understood that a polynucleotide from which a target molecule of interest is regulated or expressed may be naturally occurring in the cell which is the subject of testing or it may have been introduced into the host cell for the purpose of testing. Further, the naturally-occurring or introduced sequence may be constitutively expressed – thereby providing a model useful in screening for agents which down-regulate expression of an encoded product of the sequence wherein the down regulation can be at the nucleic acid or expression product level – or may require activation – thereby providing a model useful in screening for agents that up-regulate

expression of an encoded product of the sequence. Further, to the extent that a polynucleotide is introduced into a cell, that polynucleotide may comprise the entire coding sequence which codes for a target protein or it may comprise a portion of that coding sequence (e.g. a domain such as a protein binding domain) or a portion that regulates expression of a product encoded by the polynucleotide (e.g., a promoter). For example, the promoter that is naturally associated with the polynucleotide may be introduced into the cell that is the subject of testing. In this embodiment, where only the promoter is utilised, detecting modulation of the promoter activity can be achieved, for example, by operably linking the promoter to a suitable reporter polynucleotide including, but not restricted to, green fluorescent protein (GFP), luciferase, β -galactosidase and catecholamine acetyl transferase (CAT). Modulation of expression may be determined by measuring the activity associated with the reporter polynucleotide.

In another example, the subject of detection could be a downstream regulatory target of the target molecule, rather than target molecule itself or the reporter molecule operably linked to a promoter of a gene encoding a product the expression of which is regulated by the target protein.

These methods provide a mechanism for performing high throughput screening of putative modulatory agents such as proteinaceous or non-proteinaceous agents comprising synthetic, combinatorial, chemical and natural libraries. These methods will also facilitate the detection of agents which bind either the polynucleotide encoding the target molecule or which modulate the expression of an upstream molecule, which subsequently modulates the expression of the polynucleotide encoding the target molecule. Accordingly, these methods provide a mechanism of detecting agents that either directly or indirectly modulate the expression and/or activity of a target molecule according to the invention.

In order that the invention may be readily understood and put into practical effect, particular preferred embodiments will now be described by way of the following non-limiting examples.

EXAMPLES

EXAMPLE 1

Virus Purification and Nucleic Acid Extraction

Taro leaves showing symptoms of Alomae disease were collected from Lae, Papua New Guinea (PNG), and were either used fresh or stored at -80° C for up to 6 months before use. TaBV was purified from leaves and petioles using the method described by Lockhart and Autrey, *Plant Disease* 72:230-233, 1988. DNA was purified from the virions as described by Harper and Hull in *Virus Genes* 17:271-278, 1998, and was resuspended in TE, pH 8.0.

EXAMPLE 2

10 Total Plant Nucleic Acid Extraction

Total nucleic acid was extracted from both leaf and petiole tissue. The extraction buffer was prepared freshly by mixing equal volumes of buffer A (0.35 M sorbitol, 2% N-lauryl-sarcosine, 0.1 M Tris-HCl, pH 7.2, 4% (w/v) sodium metabisulphite) and buffer B (2 M NaCl, 0.04 M EDTA, 2% cetyltrimethylammonium bromide (CTAB), 0.1 M Tris-HCl pH 7.2). Taro tissue was ground in liquid nitrogen, and added to the extraction buffer at rate of 25 mg/mL buffer. An equal volume of chloroform was added, and the mixture incubated at 55° C for 10 min. Following centrifugation (1000 g/15 min), the supernatant was re-extracted with chloroform and the nucleic acid precipitated with an equal volume of isopropanol. Nucleic acid pellets were washed with 70% ethanol and resuspended in 100 µl TE containing RNase A (1 mg/mL).

20 EXAMPLE 3

PCR, Cloning and Sequencing

Two degenerate primers, BadnaFP and BadnaRP were designed based on the consensus sequences of the reverse transcriptase (RT) region and RNase H regions of published badnavirus sequences.

25 Badna FP 5' ATGCCITTYGGIAARAAYGCICC 3' SEQ ID NO:10

 Badna RP 5' CCAYTTTCAIACISCICCCCAICC 3' SEQ ID NO:11

DNA was amplified in 50 µL reactions containing 40 pmol of each degenerate primer, 10 mM Tris-HCl pH 8.3, 1.5mM MgCl₂, 50 mM KCl, 200 µM dNTPs and 1U *Taq* DNA polymerase (Roche) and partially purified virion preparation as template. The amplification cycle conditions were 94° C for 7 min, followed by 40 cycles of 94° C for 30 s, 50° C for 30 s, 72° C for 30 s, and a final

extension for 72° C for 7 min. The amplified PCR product was cloned into pGEM-T (Promega pGEM®-T and pGEM®-T Easy vector system) according to the manufacturer's instructions.

Primers 1F and TRBR were used in a PCR reaction to amplify a region spanning part of the RT-coding region to the putative tRNA binding site.

5 1F 5' GGATGCAGTATTCAAAGGGTGTG 3' SEQ ID NO:12
 TRBR 5' CTGCAGGCGGCCGCGCTCTGATACCA 3' SEQ ID NO:13

Primer 1F and TRBR were designed from sequences derived from the BadnaFP/BadnaRP amplification product (with the inclusion of an *Nco* I restriction site) and the consensus sequence of the putative tRNA binding site of badnaviruses (with the additional of an anchor region which
 10 included a *Pst* I restriction site), respectively. The Expand™ Long Template PCR system (Buffer 1, Roche) was used according to the manufacturer's protocol with the PCR mix containing 0.4 µM of each specific primer and using total nucleic acid extracts as templates. The amplification conditions were 94° C for 4 min, followed by 10 cycles of 94° C for 10 s, 37° C for 30 s and 68° C for 8 min, 25 cycles of 94° C for 10 s, 55° C for 30 s and 68° C for 8 min (with 20 s increments/cycle) and a
 15 final extension for 68° C for 7 min. The resulting PCR product was A-tailed using *Taq* DNA polymerase (Roche) at 72° C for 30 min, and again cloned into pGEM-T vectors.

Primers 5F and G2R were derived from the sequence of the 1F/TRBR amplified product and were used to amplify the remainder of TaBV genome.

5F 5' AGTCTTTCCTTTGAGCTTGAGC 3' SEQ ID NO:14
 20 G2R 5' CACACCCTTTGAATACTGCATCCAT 3' SEQ ID NO:15

The amplification was optimised using the Opti-Prime™ PCR optimisation system (Stratagene) with the Pwo/*Taq* DNA polymerase blend supplied in the Expand™ Long Template PCR kit (Roche). To reduce the chance of aberrant background in the amplification, purified viral DNA was used as template. The amplification cycle conditions were 94° C for 2 min, 20 cycles of 94° C for
 25 10 s, 50° C for 30 s and 68° C for 8 min, 20 cycles of 94° C for 10 s, 55° C for 30 s and 68° C for 8 min (with 20 s increments/cycle), and a final extension for 68° C for 7 min. The resulting PCR product was A-tailed and cloned as described above.

Plasmid templates for each of the cloned products were purified using standard alkaline lysis (39). Sequencing reactions were then prepared using the ABI PRISM® BigDye™ Primer
 30 Cycle Sequencing Kits (Applied Biosystems) and the reactions purified by sodium acetate precipitation. The final precipitated products were then sent for gel separation analysis at the Australian Genome Research Facility (AGRF), University of Queensland.

EXAMPLE 4**Sequence Analysis**

Sequence assembly and contig analysis of all the clones were performed with the aid of the computer software, SeqMan II Version 4.06, included in the Lasergene 99 Suite DNASTAR.

5 The sequence of TaBV was analysed for the presence of open reading frames (ORFs), and the deduced amino acid sequences of the corresponding ORFs were created using the EditSeq™ program (in DNASTAR). Nucleotide and deduced amino acid sequences of TaBV and other badnaviruses were aligned and compared using the MegAlign™ program (in DNASTAR). TaBV nucleotide sequence was analysed for potential promoter elements including TATA box and other

10 *cis*-acting regulatory elements using either EditSeq™ (in DNASTAR) and/or Search CARE included in the PlantCARE website (<http://sphinx.rug.ac.be:8080/PlantCARE/>) by which the query sequence was compared against the database of plant promoters and their *cis*-acting regulatory elements (Rombauts *et al.*, *Nucleic Acid Research* 27:295-296, 1999). Analysis for putative polyadenylation (poly A) signals was performed using the POLYA SCAN program included in the

15 GENE REGULATION website (<http://www.gene-regulation.com>) by which the query sequence was compared against the TRANSFAC database, a database on transcription factors, their genomic binding site and DNA-binding profiles (Wingender *et al.*, *Nucleic Acid Research* 28:316-319, 2000).

EXAMPLE 5**20 Purification of TaBV**

Prior to purification of TaBV, leaf dips were prepared from Alomae-diseased taro and examined by electron microscopy. Small numbers of bacilliform virus particles, approximately 125-130 nm x 25-40 nm, were observed in most plants, and tissue from these plants was pooled and used for virus purification. Examination of purified preparations revealed very few particles

25 and attempts to trap these particles by immunosorbent electron microscopy using antiserum raised against a pool of SCBV isolates was unsuccessful.

Cloning of TaBV DNA

Initial attempts to obtain a full-length clone of the TaBV genome by conventional cloning were unsuccessful due to the inability to extract sufficient quantities of DNA from the low

30 concentration of purified virions. Therefore, a PCR-based strategy was used to obtain the complete genome sequence.

The two degenerate primers, Badna FP (SEQ ID NO:10) and Badna RP (SEQ ID NO:11), described above, were used in a PCR with purified virions as template. The expected size product

of approximately 600 bp was amplified and cloned. Three clones were sequenced, and all three were found to contain inserts of 579 bp; at most, there were two nucleotide changes between the sequences. Two further primers, 1F (SEQ ID NO:12) and TRBR (SEQ ID NO:13), were subsequently designed from the consensus sequences derived from the 5' end of the three
5 BadnaFP/BadnaRP PCR clones and the putative tRNA binding site of badnaviruses, respectively. Using total taro nucleic acid as template, the expected size product of approximately 1.9 kbp was amplified and cloned. Three clones were selected for sequencing and were found to contain inserts of 1900, 1901 and 1902 bp. When the sequences were compared, there was a minimum of 98.3% similarity at the nucleotide level. Primers 5F (SEQ ID NO:14) and G2R (SEQ ID NO:15) were
10 used to obtain the remainder of the genome. These were used in a PCR with purified viral DNA as template and the expected size product of approximately 5.6 kbp was amplified. Two clones were sequenced and were found to contain inserts comprising 5671 bp and 5675 bp. At the nucleotide level, there was 99.5% similarity between the sequences.

EXAMPLE 6

15 Complete genomic sequence

The complete TaBV genomic sequence was derived from the consensus sequences of Badna FP/Badna RP, 1F/TRBR-derived clones, and the 5671 bp 5F/G2R-derived clone. This latter clone was chosen because it was deemed to represent the minimal length of viral sequence found in infected plants. The complete sequence of the PNG isolate of TaBV comprised 7,458 bp and had a
20 G+C content of 39.3%. The conserved plant cytoplasmic initiator methionine tRNA (tRNA^{met}) binding site was identified in the TaBV genome:

tRNA^{met} binding site 5' TGGTATCAGAGC 3' SEQ ID NO:16

and the numbering of the TaBV genomic sequence is consistent with other badnaviruses, beginning at the first nucleotide of the putative tRNA^{met}-binding site.

25 A map showing the genomic organisation of TaBV is provided as Figure 1.

EXAMPLE 7

Cloning of the TaBV-derived promoter fragments

Two recombinant plasmids, one containing the TaBV genomic region spanning from 3' terminus of RT-coding region to the putative tRNA binding site and the other one containing the
30 remainder of TaBV genomic region, were used as templates to create TaBV-derived promoters using PCR. Sizes of PCR products, PCR primers, TaBV genomic region targeted for PCR

amplification and the cloning strategy are listed in Table 1 and illustrated schematically in Figure 2A.

TABLE 1

<u>Designation</u>	<u>Size (bp)</u>	<u>Position start/end of TaBV genome</u>	<u>Primers forward/reve rse</u>	<u>Primer sequence</u> <u>Sequence ID Number</u>
T600	598	6873/12	F-GTN/ R-GTN	5' CTGCAGATAGGATTCTTTGTGTGTG SEQ ID NO:17 5' CCATGGGCTCTGATACCAAGGTAG SEQ ID NO:18
T500	529	6942/12	P527-F/ R-GTN	5' CTGCAGGGACGCCACTAGGC SEQ ID NO:19 5' CCATGGGCTCTGATACCAAGGTAG SEQ ID NO:18
T250	260	7211/12	P257-F/ R-GTN	5' CTGCAGGCCACCTCATCGGTTGC SEQ ID NO:20 5' CCATGGGCTCTGATACCAAGGTAG SEQ ID NO:18
T100	115	7356/12	P114-F/ R-GTN	5' CTGCAGGAGCTTGAGCTTGTGTG SEQ ID NO:21 5' CCATGGGCTCTGATACCAAGGTAG SEQ ID NO:18
Tas-1/TR	1190	6281/12	FP-as-1/ TRBR-Bam	5' CTGCAGGCCTTCACGGGTTAGATG SEQ ID NO:22 5' GGATCCGCTCTGATACCAAGGTAG SEQ ID NO:23
T6765/TR	706	6765/12	FP-6765-pro/ R-GTN	5' CTGCAGGGGGAGATTGGCTGC SEQ ID NO:24 5' CCATGGGCTCTGATACCAAGGTAG SEQ ID NO:18
PTnot600 bgl	598	6873/12	P600Not-F/ P600Bgl-R	5' GGAAGCTTGCGGCCGCCGAGAAGGTTGC SEQ ID NO:25 5' GCGGAAGATCTTGCTCTGATACCAAGGTAG SEQ ID NO:26
T6765L	1029	6765/335	FP-6765-pro/ RP-leader	5' CTGCAGGGGGAGATTGGCTGC SEQ ID NO:24 5' CCATGGATCATATAATTGTAAGGTGCG SEQ ID NO:27

5 The Expand™ PCR system (Boehringer) was used according to the manufacturer's protocol with the PCR mix containing 0.4 μM of each primer and 20-40 ng plasmid DNA as template. The amplification cycle conditions were 94° C for 2 min, followed by 10 cycles of [94° C for 10 s, 50° C for 30s and 68° C for 5 min], 30 cycles of [94° C for 10 s, 55° C for 30s and 68° C

for 8 min] and a final extension for 68° C for 10 min. The resulting PCR products were A-tailed using *Taq* DNA polymerase (Roche) at 72° C for 30 min, purified using High Pure PCR Product Purification Kit (Roche) and cloned into pGEM®-T easy vector (Promega) according to the manufacturer's protocol. Plasmids containing cloned fragments are referred to according to their designated name in Table 1 and Figure 2A. For example, pGEM®-T containing the T600 fragment was named pGEM-T600. All clones were sequenced in both directions using an ABI PRISM® BigDye™ Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems) and automated sequencer at the Australian Genome Research Facility (AGRF), University of Queensland, Australia. Initially, the primers used to amplify the fragments from TaBV genomic clones were used as sequencing primer. For longer fragments internal primers were also used.

EXAMPLE 8

Construction of Transformation Plasmids

The TaBV promoter fragments were subsequently fused to reporter genes coding for either GUS or GFP, generating transformation constructs for microprojectile bombardment and *Agrobacterium*-mediated transformation. The organisation of promoter fragments that were not directly PCR generated from TaBV genomic clone but instead were derived from the original PCR fragments are illustrated diagrammatically in Figure 2B. All plasmids which were provided by others and, used directly in transformation experiments, are illustrated diagrammatically in Figure 3. Plasmids p35S-GFP, pUbi-GFP, p35S-GFP/BT6.3-NPT and pBT6.3-Ubi-NPT were supplied by the Centre for Molecular Biotechnology, Queensland University of Technology, Australia. Plasmids p35S-GFP and pUbi-GFP were used as positive controls for comparisons of GFP expression directed by different promoters. The plasmid p35S-GFP/BT6.3-NPT was used as a CaMV35S-GFP control in plants stably transformed using particle bombardment while pBT6.3-Ubi-NPT was used for co-transformation with other test and control plasmids that did not contain a selectable marker (Becker *et al.*, *Plant Cell Rep* 19:229-234; Dugdale *et al.*, *J Gen Virol* 79:2301-2311, 1998) Plasmids used for comparisons of GUS expression directed by different promoters were pGUS2 and pUGR73 (Christensen and Quail, *Transgenic Res* 5:213-218, 1996). Binary vectors p2302 and p2304 were used as positive controls and were supplied by the Centre for Molecular Biotechnology, Queensland University of Technology, Australia.

For the construction of transformation plasmids for microprojectile bombardment, all restriction enzyme digested promoter fragments and vectors were either gel purified using QIAquick® Gel Extraction Kit (QIAGEN) or directly purified after PCR using High Pure PCR Product Purification Kit (Roche) according to the manufacturers' protocols. One unit of T4 DNA ligase (Promega) was used for each ligation according to the manufacturer's protocol. The vectors

pGEM-BS2P-GFP-NOS and pBaI-S-GUS-Rbc were also supplied by the Centre for Molecular Biotechnology, Queensland University of Technology, Australia. The plasmid pGEM-BS2P-GFP-NOS contained a promoter derived from banana bunchy top virus upstream of GFP and a NOS terminator. The plasmid pBaI-S-GUS-Rbc contained a promoter derived from the banana actin gene upstream of GUS and the terminator from the tobacco ribisco gene. These promoter fragments were removed from both pGEM-BS2P-GFP-NOS and pBaI-S-GUS-Rbc by *PstI/NcoI* digestion to allow for insertion of the TaBV derived promoters as *PstI/NcoI* fragments. The *PstI/NcoI* fragments of promoter clones (pGEM-T600, pGEM-T500, pGEM-T250, pGEM-T100) were subcloned into *PstI/NcoI* digested vectors, pGEM-BS2P-GFP-NOS and pBaI-S-GUS-Rbc, creating pT600-GFP, pT600-GUS, pT500-GFP, pT500-GUS, pT250-GFP, pT250-GUS, pT100-GFP and pT100-GUS, respectively. The *PstI/XbaI* fragment from pGEM-Tas-1/TR was placed upstream of the *XbaI/NcoI* fragment from pGEMT-6765/TR in a single directional cloning step into *PstI/NcoI* digested vectors, pGEM-BS2P-GFP-NOS and pBaI-S-GUS-Rbc, respectively, creating pT1200-GFP and pT1200-GUS.

Using the same cloning strategy, the *PstI/XbaI* fragment from pGEM-Tas-1/TR was placed upstream of *XbaI/NcoI* digested pGEM-T6765L into *PstI/NcoI* digested, pGEM-BS2P-GFP-NOS and pBaI-S-GUS-Rbc, to create pT1200L-GFP and pT1200L-GUS. The plasmids pT1200L-GFP and pT1200L-GUS were *PstI/XbaI* digested to remove part of the 5' region of the promoter, blunt ended using T4 DNA polymerase (Boehringer) and subsequently re-ligated creating pT600L-GFP and pT600L-GUS. The Ubi-1 promoter was removed from pUGR73 using *NotI* and *BglII* leaving the Ubi-1 intron, GUS gene and RbcS terminator in place. The *NotI/BglII* fragment from pGEM-Tnot600bgl was then ligated into pUGR73 from which the Ubi-1 promoter had been removed, creating pT600UGR.

For the construction of plasmids for *Agrobacterium*-mediated transformation, constructs containing TaBV-derived promoter-GFP/GUS reporter genes-terminator expression cassettes were cloned into the binary vector, pCambia2300 (CAMBIA) which contained a multiple cloning site and a CaMV 35S promoter-*nptII*-CaMV 35S terminator expression cassette. The *PstI/EcoRI* digested fragments from pT1200-GFP, pT600-GFP and pT500-GFP were cloned into *PstI/EcoRI* digested pCambia2300, creating pCambiaT1200-GFP, pCambiaT600-GFP and pCambiaT500-GFP respectively. TaBV derived promoter fragments together with the GUS gene were removed from pT1200-GUS, pT600-GUS and pT500-GUS using *PstI* and *SmaI*. The Rbc S terminator region was removed from pT1200-GUS, using *PstI* and *EcoRI*. Both promoter GUS fragment and terminator region were cloned into *PstI/EcoRI* digested pCambia2300 in one step, creating pCambiaT1200-GUS, pCambiaT600-GUS and pCambiaT500.

EXAMPLE 9**Plant Material**

Tissue cultured taro plantlets (*Colocasia esculenta* var. *antiquorum*) were originally from Palau and supplied by Mary Taylor (SPC, Fiji). Explants were multiplied on media containing MS Salts, 100 mg l⁻¹ myo-inositol, 0.4 mg l⁻¹ thiamine-HCl, 30 g l⁻¹ sucrose, 1.0 mg l⁻¹ BAP 0.30 mg l⁻¹ NAA, and 2 g l⁻¹ Phytigel (Sigma), pH 5.6. Taro plantlets were maintained at 25° C with a 16 h photoperiod.

The embryogenic suspension culture of banana cv Ladyfinger (*Musa* spp. AAB) was generated and maintained as described by Becker *et al.* (supra) with the exception that embryogenesis was induced on media containing 2,4-D at 2 mg/L instead of 4mg/L.

The tobacco suspension culture was initiated and maintained as follows. Approximately 10 tobacco (*Nicotiana tabacum* cv. Dynes) seeds were placed in 50 mL of liquid media (MS salts, 100 mg/L myo-inositol, 0.5 mg/L nicotinic acid, 0.5 mg/L pyridoxine, 0.4 mg/L thiamine, 200 mg/L glycine, 0.222 mg/L 2,4-D, 30 g/L sucrose, pH 5.7) in a 250 mL Erlenmeyer flask, and cultured in the dark on an orbital shaker (70 rpm) at 25° C. Half the media was replaced with fresh media every 7 days. After two months, callus cells sloughed off into suspension were separated from the original seed material. Suspension cells were then cultured in the light (16 h photoperiod) and subcultured every 7 days adding 5 mL of cell suspension to 45 mL of fresh liquid media.

EXAMPLE 10**Transient activity in taro, tobacco and banana**

Leaves from tissue cultured taro plantlets were excised 2h prior to transformation and placed in MS salts liquid media. The leaves were then placed abaxial side-up, transferred onto the media containing 25 mL of MS salts and 5 g l⁻¹ Phytigel (Sigma) in 90 mm diameter Petri dishes prior to microprojectile bombardment. Tobacco cells were prepared prior to bombardment as per Dugdale *et al.* (supra), and banana cells were prepared as per Becker *et al.* (supra). All transformation constructs used for microprojectile bombardment were prepared using a Bresapure Plasmid Maxi Kit (Geneworks) according to the manufacturer's instructions. Transient expressions of reporter genes in taro leaves were assessed 72 h post bombardment whereas in tobacco and banana the activity was assessed 48 h post bombardment.

EXAMPLE 11**Banana and tobacco transformation and regeneration**

The stable transformation and regeneration of banana plants were essentially as described by Becker *et al.* (supra). Banana was co-transformed with TaBV promoter expression vectors and selectable marker expression vector (pBT6.3-Ubi-NPT) by mixing the plasmids at equimolar concentrations prior to coating of gold particles. Prior to tobacco transformation, *Agrobacterium* (strain AGL1) containing binary vectors were cultured at 28°C in YT broth containing 100 µg/mL kanamycin and 200 µM acetosyringone. Stably transformed tobacco (*Nicotiana tabacum* cv. Samsun) were generated using leaf disk transformation essentially as described by Horsch *et al.* (In: Gelvin SB, Schilperoort RA (eds) *Plant Molecular Biology Manual*, Kluwer, Dordrecht, 1998). Transgenic tobacco plants were regenerated on media containing 50 mg/L geneticin and, to kill residual *Agrobacterium*, 200 mg/L timentin.

EXAMPLE 12**Analysis of Transgenic Plants**

Total genomic DNA of lines of regenerated transgenic banana or tobacco was extracted from leaf material of 2-3-month-old tissue culture plants essentially as described by Stewart and Via (*Biotechniques* 14:748-750, 1993). Genomic DNA (10-15 µg) was digested with *Nco*I, for transgenic banana, or *Apa*I, for transgenic tobacco, electrophoresed in a 1% agarose gel, capillary-blotted onto a positively charged nylon blotting membrane (Roche) and baked for 2h at 80° C. Prior to hybridisation, the membrane was blocked for 60 min at 42° C with DIG Easy Hyb™ (Roche). A 1.8 kbp DNA probe containing the complete *uidA* gene sequence was PCR amplified and DIG-labelled, which was used to detect the presence of *uidA* gene in the genomic DNA restriction digested fragments. The PCR DIG Labelling Mix system (Boehringer) was used according to the manufacturer's protocol with the PCR mix containing 0.4 µM of each primer-GUS1 and GUS2:

GUS1 5' ATGTTTACGTCCTGT SEQ ID NO:28

GUS2 5' TTA CTTGTTTGC SEQ ID NO:29

and 40 ng PT600GR as template. The amplification cycle conditions were 94° C for 4 min, followed by 35 cycles of [94° C for 50 s, 50° C for 50s and 72° C for 2 min], and a final extension for 72° C for 10 min. The membrane was hybridised with DIG-labelled probe for 20 hr at 42° C, washed as described by Hermann *et al.* (*Plant Cell Rep* 20:525-530, 2001), and detected using CDP-STAR system (Roche) according to the manufacturer's instructions. Hybridisation signal was detected with CURIX ORTHO HT-G 100 NIF ECOPAC medical X-ray film (AGFA).

EXAMPLE 13**Reporter Gene Assays and Detection**

GFP expression was visualised using a Leica MZ12 stereo microscope with GFP-Plus fluorescence module. GUS activity was assayed histochemically and fluorometrically essentially as described by Jefferson *et al.* (*EMBO J* 6:3901-3907, 1987). Fluorescence was measured using a Perkin Elmer LS50B luminescence spectrophotometer.

EXAMPLE 14**Cloning of putative promoter sequences from TaBV into promoter-reporter constructs**

Sequence analysis of the TaBV genome led to the identification of putative promoter elements, such as a TATA box and sequences similar to CaMV as-1 sequence (Yin and Beachy, *Plant J* 7: 969-980, 1995). A region of the TaBV genome containing potential promoter elements was chosen to generate a series of promoter fragments by PCR which were then cloned into expression vectors upstream of either the GUS or GFP reporter genes.

EXAMPLE 15**Transient assays of TaBV promoter activity in taro, banana and tobacco**

Currently, there is no routine transformation system available for taro. Therefore, leaves from *in vitro* taro plantlets were used as microprojectile target tissue in transient assays. The activity of the TaBV-derived promoter fragments T100, T250, T500, T600, T600L, T1200 and T1200L were compared to that of the maize polyubiquitin-1 (Ubi-1) and cauliflower mosaic virus 35S (CaMV35S) promoters. Based on the presence of blue foci after histochemical GUS staining and also green fluorescent foci when GFP was used, T500, T600, T1200 and T1200L were active in taro leaf. The precise number of foci was not counted. However, these promoter fragments and the CaMV35S promoter appeared to result in a lower number of foci in comparison to Ubi-1 (Figure 4). T100, T250 and T600L had no detectable activity.

The activity of TaBV-derived promoter fragments that were shown to direct expression in taro leaf was then quantified via fluorometric GUS assay. The result of this assay was consistent with that of the histochemical staining with the activity of T500, T600, T1200 and T1200L being similar to that of CaMV35S and approximately 10-15% of Ubi-1 (Figure 5).

Promoter fragments T500, T600, T600 with Ubi-1 intron (T600U) and T1200 were all shown to be active in transient assays in banana suspension cells. Based on the number of blue foci (GUS) and green fluorescent foci (GFP) their activity appeared to be lower than that of Ubi-1 and

CaMV35S. Interestingly, the addition of the Ubi-1 intron to T600 did not appear to enhance expression but rather resulted in a reduction.

In tobacco suspension cells, T500, T600 and T1200 promoter fragments were also active as indicated by the presence of many blue foci and green fluorescent foci. However, the number of foci did not appear to be as great as in cells bombarded with CaMV35S expression vectors.

EXAMPLE 16

Activity of TaBV promoter in stably transformed banana and tobacco

Preliminary results from transient assays in banana and tobacco indicated that TaBV-derived promoter fragments T500, T600 and T1200 were active in a monocotyledonous (banana) and dicotyledonous (tobacco) species. Therefore, the activity of these promoter fragments in stably transformed banana and tobacco was assessed. In banana transformed with T500, T600, T1200 and CaMV35S GFP expression vectors, strong green fluorescence was observed in leaf, pseudostem and root tissue, whereas only the red fluorescence from chlorophyll was observed in non-transformed control plants (Figure 6). There did not appear to be any difference in the pattern of expression between the different promoter fragments. All appeared to direct expression in a constitutive manner. However, green fluorescence was greater in newly emerged leaves and vascular tissue.

To quantify the activity of the promoter fragments, between 4 and 12 transgenic banana lines were generated for each GUS expression vector. These lines were confirmed as being derived from individual transformation events by Southern blot analysis. Fluorometric GUS assays on these independent lines revealed that Ubi-1, T500 and T1200 all directed similar levels of expression while T600 activity was approximately four-fold greater than that of the other promoter fragments and Ubi-1 (Figure 7).

In transgenic tobacco, the pattern of GFP expression was difficult to determine due to the green fluorescence being obscured by bright red chlorophyll fluorescence. Therefore, the pattern of expression directed by the TaBV-derived promoter fragments was assessed by histochemically staining GUS transformed plant tissue. The double CaMV35S promoter and T500, T600 and T1200 promoter fragments all directed GUS expression in leaves, stems and roots (Figure 8). More intense blue staining was observed in vascular tissue of the stem and in the root tips. Between 5 and 7 transgenic tobacco lines were generated for each GUS expression vector. These lines were confirmed as being derived from individual transformation events by Southern blot analysis. Fluorometric GUS assays on these independent lines revealed that the activity of the double

CaMV35S was, depending on the fragment length, between approximately four and ten-fold greater than the TaBV derived promoter fragments (Figure 9).

5 Interestingly, the activity the TaBV-derived promoter fragments relative to each other was different in banana and tobacco. In banana, truncating the promoter region from T1200 to T600 resulted in increased expression. Further truncation from T600 to T500 reduced expression levels. In tobacco, the inverse was true where, to a lesser degree, truncating the promoter region from T1200 to T600 decreased expression levels and further truncation from T600 to T500 increased expression levels again.

10 The disclosure of every patent, patent application, and publication cited herein is hereby incorporated herein by reference in its entirety.

The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.

15 Throughout the specification the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. Those of skill in the art will therefore appreciate that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of the present invention. All such modifications and changes are intended to be included within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated DNA molecule comprising a promoter or biologically active fragment thereof or variant of these, wherein the promoter is located upstream of a transcribable DNA sequence that hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions.
2. The DNA molecule of claim 1, wherein the transcribable DNA sequence is obtained from a virus.
3. The DNA molecule of claim 1, wherein the transcribable DNA sequence is obtained from a badnavirus.
4. The DNA molecule of claim 2 or claim 3, wherein the transcribable DNA sequence is expressed constitutively in a monocotyledonous plant.
5. The DNA molecule of claim 2 or claim 3, wherein the transcribable DNA sequence is expressed constitutively in a non-graminaceous monocotyledonous plant.
6. The DNA molecule of claim 5, wherein the non-graminaceous monocotyledonous plant is selected from the group consisting of *Musaceae*, taro, ginger, onions, garlic, pineapple, bromeliaeds, palms, orchids, lilies and irises.
7. The DNA molecule of claim 5, wherein the non-graminaceous monocotyledonous plant is taro.
8. The DNA molecule of claim 1, wherein the promoter comprises the sequence set forth in SEQ ID NO:6.
9. The DNA molecule of claim 8, wherein the biologically active fragment is selected from the group consisting of SEQ ID NO:7, 8 and 9.
10. The DNA molecule of claim 8, wherein the variant has at least 30% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6, 7, 8 and 9.
11. The DNA molecule of claim 8, wherein the variant is capable of hybridising to a sequence selected from the group consisting of SEQ ID NO: 6, 7, 8 and 9 under at least low stringency conditions.
12. An isolated polynucleotide comprising a nucleotide sequence that corresponds or is complementary to at least a portion of the sequence set forth in SEQ ID NO:1 or to a variant thereof.

13. The polynucleotide of claim 12, wherein the variant displays at least 30% sequence identity to at least a portion of the sequence set forth in SEQ ID NO:1, which is at least 18 nucleotides in length.
14. The polynucleotide of claim 13, wherein the variant displays at least 30% sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NO:3, 4 and 5.
15. The polynucleotide of claim 12, wherein the variant hybridises to at least a portion of the sequence set forth in SEQ ID NO:1, which is at least 18 nucleotides in length, under at least low stringency conditions.
16. The polynucleotide of claim 15, wherein the variant hybridises to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NO:3, 4 and 5 under at least low stringency conditions.
17. An isolated polypeptide comprising an amino acid sequence that corresponds to at least a portion of the sequence set forth in any of SEQ ID NO:3, 4 or 5 or of a variant that displays at least 30% sequence identity to that sequence, wherein the portion is at least 6 amino acid residues in length.
18. A chimeric DNA construct comprising an isolated promoter or biologically active fragment thereof or variant of these, wherein the promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions, wherein the promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed.
19. The construct of claim 18, further comprising a 3' non-translated sequence that is operably linked to the foreign or endogenous DNA sequence and that functions in plant cells to terminate transcription and/or to cause addition of a polyadenylated nucleotide sequence to the 3' end of a transcribed RNA sequence.
20. The construct of claim 18, wherein the promoter comprises the sequence set forth in SEQ ID NO:6.
21. The construct of claim 18, wherein the biologically active fragment is selected from the group consisting of SEQ ID NO:7, 8 and 9.
22. The construct of claim 18, wherein the variant has at least 30% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6, 7, 8 and 9.

23. The construct of claim 18, wherein the variant is capable of hybridising to a sequence selected from the group consisting of SEQ ID NO: 6, 7, 8 and 9 under at least low stringency conditions.
24. The construct of claim 18, wherein the foreign or endogenous DNA sequence encodes a structural or regulatory protein.
- 5 25. The construct of claim 18, wherein the foreign or endogenous DNA sequence encodes a transcript capable of modulating expression of a corresponding target gene.
26. The construct of claim 25, wherein the transcript comprises a transcribed region aimed at downregulating the expression of the corresponding target gene.
27. The construct of claim 25, wherein the transcript comprises a transcribed region that represents
10 a molecule selected from the group consisting of a sense suppression molecule, an antisense RNA, a ribozyme and an RNAi molecule.
28. The construct of claim 18, further comprising an enhancer element.
29. The construct of claim 18, further comprising a leader sequence which modulates mRNA stability.
- 15 30. The construct of claim 18, further comprising a targeting sequence for targeting a protein product of the foreign or endogenous DNA sequence to an intracellular compartment within plant cells or to an extracellular environment.
31. The construct of claim 18, further comprising a selectable marker gene.
32. The construct of claim 18, further comprising a screenable marker gene.
- 20 33. The construct of claim 18, wherein the promoter or biologically active fragment or variant is constitutively expressed in a host cell.
34. The construct of claim 33, wherein the host cell is a plant cell.
35. The construct of claim 33, wherein the host cell is a monocotyledonous plant cell.
36. The construct of claim 33, wherein the host cell is a non-graminaceous monocotyledonous
25 plant cell.
37. The construct of claim 33, wherein the host cell is a non-graminaceous monocotyledonous plant cell selected from the group consisting of *Musaceae*, taro, ginger, onions, garlic, pineapple, bromeliaeds, palms, orchids, lilies and irises.

38. The construct of claim 33, wherein the host cell is a graminaceous monocotyledonous plant cell.
39. The construct of claim 33, wherein the host cell is a dicotyledonous plant cell.
40. A method for gene expression in a plant, comprising introducing into a plant cell a chimeric DNA construct comprising an isolated promoter or biologically active fragment thereof or variant of these, wherein the promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions, wherein the promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed
41. A method for producing transformed plant cells, comprising:
- (a) introducing into regenerable plant cells a chimeric DNA construct comprising an isolated promoter or biologically active fragment thereof or variant of these, wherein the promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions, wherein the promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed, so as to yield transformed plant cells; and
 - (b) identifying or selecting transformed plant cells.
42. A method for selecting stable genetic transformants from transformed plant cells comprising:
- (a) introducing into regenerable plant cells a chimeric DNA construct comprising an isolated promoter or biologically active fragment thereof or variant of these, wherein the promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions, wherein the promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed, so as to yield transformed plant cells; and
 - (b) identifying or selecting a transformed plant cell line from said transformed plant cells.
43. A method for producing a differentiated transgenic plant, comprising:
- (a) introducing into regenerable plant cells a chimeric DNA construct comprising an isolated promoter or biologically active fragment thereof or variant of these, wherein the promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions, wherein the promoter or biologically active fragment or variant

is operably linked to a foreign or endogenous DNA sequence to be transcribed, so as to yield regenerable transformed plant cells;

- (b) identifying or selecting a population of transformed plant cells; and
- (c) regenerating a differentiated transgenic plant from the population.

- 5 44. The method of any one of claims 40 to 43, wherein the cells are dicotyledonous plant cells.
45. The method of any one of claims 40 to 43, wherein the cells are monocotyledonous plant cells.
46. The method of any one of claims 40 to 43, wherein the cells are graminaceous monocotyledonous plant cells.
47. The method of any one of claims 40 to 43, wherein the cells are non-graminaceous
10 monocotyledonous plant cells.
48. The method of any one of claims 40 to 43, wherein expression of the chimeric DNA construct in the transformed cells imparts a phenotypic characteristic to the transformed cells.
49. The method of any one of claim 40 to 43, wherein the construct comprises a selectable marker gene.
- 15 50. The method of any one of claim 40 to 43, wherein the construct comprises a screenable marker gene.
51. The method of claim 43, wherein expression of the chimeric DNA construct renders the differentiated transgenic plant identifiable over the corresponding non-transgenic plant.
52. The method of claim 43, further comprising obtaining progeny from the differentiated
20 transgenic plant.
53. Progeny obtained by the method of claim 52.
54. A plant part of the differentiated transgenic plant obtained from the method of claim 43, wherein the plant part contains the chimeric construct.
55. A differentiated transgenic plant regenerated from transformed plant cells obtained by the
25 method of claim 41.
56. A transformed plant cell containing a chimeric DNA construct comprising an isolated plant promoter or biologically active fragment thereof or variant of these, wherein said promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low

stringency conditions, wherein said promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed.

57. A differentiated transgenic plant comprising plant cells containing a chimeric DNA construct comprising an isolated plant promoter or biologically active fragment thereof or variant of these, wherein said promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions, wherein said promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed.
58. The transgenic plant of claim 57, wherein the plant is a dicotyledonous plant.
59. The transgenic plant of claim 57, wherein the plant is a monocotyledonous plant.
60. The transgenic plant of claim 57, wherein the plant is a graminaceous monocotyledonous plant.
61. The transgenic plant of claim 57, wherein the plant is a non-graminaceous monocotyledonous plant.
62. The transgenic plant of claim 57, wherein the construct comprises a selectable marker gene.
63. The transgenic plant of claim 57, wherein the construct comprises a screenable marker gene.
64. The transgenic plant of claim 57, wherein the expression of the chimeric DNA construct renders the differentiated transgenic plant identifiable over the corresponding non-transgenic plant.
65. Use of a chimeric DNA construct comprising an isolated plant promoter or biologically active fragment thereof or variant of these, wherein said promoter is naturally located upstream of a transcribable DNA sequence which hybridises to a nucleic acid probe derived from the polynucleotide sequence set forth in SEQ ID NO:1 under at least low stringency conditions, wherein said promoter or biologically active fragment or variant is operably linked to a foreign or endogenous DNA sequence to be transcribed, in the production of a transformed plant cell, plant or plant part.
66. A method for diagnosing a badnaviral infection of a plant, comprising detecting the presence in a cell or tissue of the plant of (a) a nucleotide sequence that corresponds or is complementary to at least a portion of the nucleotide sequence set forth in SEQ ID NO:1 or 2, or of a variant of the nucleotide sequence, or (b) an amino acid sequence that corresponds to at least a portion of the sequence set forth in SEQ ID NO:3, 4 or 5, or of a variant of the amino acid sequence.

67. A method of screening for an agent that modulates badnaviral infection, the method comprising:

– contacting a preparation comprising:

(i) a polypeptide comprising an amino acid sequence that corresponds to at least a portion of the sequence set forth in SEQ ID NO: 3, 4 or 5, or of a variant of the sequence; or

(ii) a polynucleotide comprising a nucleotide sequence that corresponds or is complementary to at least a portion of the sequence set forth in SEQ ID NO:1 or 2, which polynucleotide is operably linked to a promoter; or

(iii) a polynucleotide comprising a reporter gene that is operably connected to a promoter comprising the sequence set forth in SEQ ID NO:6, 7, 8 or 9,

with a test agent; and

– detecting a change in the level and/or functional activity of the polypeptide, or an expression product of the nucleotide sequence or of the reporter gene, relative to a normal or reference level and/or functional activity in the absence of the test agent.

68. The method of claim 67, wherein the agent inhibits or reduces badnavirus infection and the method comprises detecting a reduction in the level and/or functional activity of the polypeptide, or an expression product of the nucleotide sequence or of the reporter gene, relative to the normal or reference level and/or functional activity.

69. A method for treating and/or preventing badnaviral infection of a plant, comprising administering to the plant an agent that:

– reduces the level and/or functional activity of:

a polypeptide that comprises an amino acid sequence corresponding to at least a portion of the sequence set forth in SEQ ID NO: 3, 4 or 5, or of a variant of the sequence; or

an expression product of a nucleotide sequence that corresponds or is complementary to at least a portion of the sequence set forth in SEQ ID NO:1 or 2; or

– reduces the functional activity of a promoter that comprises the sequence set forth in any one of SEQ ID NO:6, 7, 8 or 9.

10/521571

1/9




FIGURE 1

10/521571

2/9




FIGURE 2

3/9




FIGURE 3

10/521571

4/9





FIGURE 4

5/9



(Taro leaf)

FIGURE 5

10/521571

6/9




FIGURE 6

7/9




FIGURE 7





FIGURE 8

10/521571

9/9



(Tobacco)

FIGURE 9

10/521571

DT09 Rec'd PCT/PTO 1.8 JAN 2005

SEQUENCE LISTING

<110> Harding, Robert Maxwell
 Dale, James Langham
 Becker, Douglas Keith
 Hafner, Gregory John
 Yang, Ilin

<120> Transcriptional Control Element, Chimeric Constructs and Uses
 Therefor

<130> 12177232

<140> Unassigned

<141> 2003-07-17

<150> USSN 60/396,912

<151> 2002-07-17

<160> 29

<170> PatentIn version 3.2

<210> 1

<211> 6523

<212> DNA

<213> Taro bacilliform virus

<400> 1

```

atggcaaaga aatttgaagc agctattaaa gactgggatg ataactctcg acgagcagat      60
ctttcctatc ttgacctagc caccactaca aaaccttctg catcacaatt agtcataat      120
ctacaagtca tttttgatag attatcctta cattcttcag tctccattaa ggaacattac      180
gaagtagtta gcaaacttca ttctttggaa aaatctatag aagaattaa gtctgaattg      240
actacggtca aaagggcttt aacttctatc caaaaagaag ttttcacca caaacccctc      300
acagcacagg aagtgcaaac ccttgacaaa agtctgatca aagaacctaa gcaaatagaa      360
cagcaggccg tatttcttct aaaggagctt aaagaacaaa cagcaaaaat tcaagctttg      420
ctccacgagc ttaaaagttg atgtctgtac ctaattccac ataccaggg tacatcaaaa      480
gtttagaaga aacaaaagtc ttaggagatc catctgtagg attctctgaa attcctacca      540
ctgctatcgg aaccgctaca ggtttttcaa ctctttataa gcagaacaat acaatcatca      600
atctgcttat atctcttcac aaaaagggtg atagcctctc caaaaagaca gacgtcgacg      660
agttagccac tgagttgtcc aaactcacia tcaaggatac cccaaagggtt aaggctaaaa      720
ctcctctata cgtcttcaag agtccccgtc ttatcctcga agaggaaaga tataaaatcg      780
gccttcctcc taccactacc gattggactt ggctgttagg acatcctttt gctcctccac      840

```

caaaaacatc caciaaggca tccacctctt cttaaagatg tcttttagcag ttcgtgatcg 900
tggttccaac cettccacct cttctacagt ccctagtcag caggaccaga ttcgggatta 960
tagaaacatg caaagagttc gtcatacagc ggaaagagca gcaaggagaa tcttccctgg 1020
aagattcaat agaactctgg aatcacaaat caatccagag gcagaaatcc gtctttctca 1080
acaaagacga gcagcaatgg tcccagcaga agtattatac aatacttctc catcaacaag 1140
aatcagaaa gtgtatcagc actattctga agaaagaatt ctttgtacag gacaaaatca 1200
gcaattaaat ttgccattta ttaatgaatc ttcttacaga gccctcagag aatcagggtca 1260
acagcatctt cacataggcc tgatcatgat tegtgtacat cctcttcacg ggcgaaatgc 1320
aggaacgaca gctcttattg tccctcgaga cataagatgg aatgatgaca gatctatcat 1380
tggcaccatg gagatagatc tcagcgccgg atcccaaatt gtttatattg ccccaaatat 1440
catgctatct gttgaagatt tttatcgcaa catacaactt gcgattcaaa ctcagggcta 1500
tgaaaactgg aactctgccg agagtaactt gtcacatctc cgcgctctta ttggctgtct 1560
gacaaacgac agttttacag gattccagta caatatctct aatggttgctg agtacttgca 1620
cagtcatggg gtgcaagcta ttgaaggaca agtcaccca agaaccctcg gcaatcgatg 1680
gatcctacaa gcaccagcac caccaaggtc tctcgttcca caaaacgtgg agaccaccac 1740
tcttctggat ggtaatgtgt ctatacgttt ctccaattac catcaagcac cagttaatga 1800
tactcaggat aattctcatc ctgatatcca agaagacgaa aaccaattca ttggttttct 1860
ttctgatttg ggggaagaat atgaattgga gtatccttct ttcactccag ttcatgcaga 1920
tgaattcatt tttataatca ttaatgggga agaaattccc gatgattttg tctcatcttt 1980
ttgttccaat ttctctctc caccaattcc agaaccagaa cccacagcca ttgaagaaac 2040
agcttttaact ttggaagaac aattcaatga cctggactat cctaccctca tttcaatgga 2100
aaaacaatta gtccagtctt cagttacttc agcttacaac ccaccacag aacctcttat 2160
gggtcaggta gtctatccac cagcatctgc acctagacca caagctgaaa cttcttcaac 2220
ctctgaaaga ttcaaaaatt tcagagcaaa gccatatagt accccgacta ttttctacc 2280
tccagcatac aatcaacaag gggctatatt agttcttctt gatgacattg gcttatatga 2340
agataccatt tctcgttggg agtcattac tctcaacatg atgaatgaaa aggtttggcc 2400
atcaaatgaa gcaaaggcca aatatatgga aaatctctta ggagaaatgg agaagaagac 2460
atggatacaa tggaggacca catatgtatc cgaatatgat gctttggtcc aacaaagtga 2520

tgaaacacag aacctcctgt ctcaggtaag gaggatattt ctgctacaag acccatatca 2580
aggatcaact gcggaacaag atcaggcata taatgatctt gaaagaattt cttgtgataa 2640
tattaaggat ttaattcctt atctgattca gttccgcaat ttagctgcaa aatctggacg 2700
cttgttctta ggtccagaat tatctgaaaa attattcaga aaaatgccgc ctctaataagg 2760
caaagaaatt gaaacagcat tcatagcaaa gcatggtaat gcaaacatca ctgttatgcc 2820
tcgcattcat tttgcttacc attatcttgc tgaattatgt aaaaaggcag cattacagag 2880
atcattgaag gatctcagct tctgcaacca gattcctctc ccaggaatct atacaaaagg 2940
caacaagaag tttggtcttc gaaaggccag aacatacaaa ggaaaaccac atccaacaca 3000
tgtacgggta ttcaaaaagg caaaatacca gcgtacaaag aagtgc aaat gctttatatg 3060
tggtgaacca ggacattttg ctcgagaatg cacaaagcaa agaggaaata ttgtacgagc 3120
aacagtacat caagaactgg ccataccaga taattttgat gttgtttctg tggatgcaga 3180
tgaatctgac agctctggca tctacagtta ttccgaaaat gaagctcctc tgcaagaagt 3240
aaattctttc attcatgatg aaaatatctt tttcctatct gatgcagacg agtttgaaag 3300
cccacaacag catcttcatg aaacggtaaa tatgcttcaa tctagatctg cttatttacc 3360
tcaagtagct gttggagaag aaaaattgaa ttgtagtcac atttggtac aagatgttga 3420
tattccatct gataagcaca aatgccacac atgtagaaga gacactcaga aacattacag 3480
actggaatgt caaaaatgca aattcttggg ttgctcacta tgcacaattc catatctcgg 3540
aatcaccatg caattcaggc aaaagcaaaa atctcagcct gaaaacccaa acttagtccg 3600
agaattgtta gaacatgcca tttttctaga agaaaaatgc aaaaatcaag aattactgtc 3660
agaaactcag atagaaagga tagtcagttc tgaaaaacaa gtcaaatttt atggcatcct 3720
tcctacaaaa aagtccaaca aatctgctgg gtatgactta caatccaaca ttgatataga 3780
aatcccccca ggaaaatgta cagtcatttc tactggaacc tttctacaaa tgcttgacaa 3840
catgtatggg agactttag aaagaacatc tttggcaata caggggatta cagtacaagg 3900
aggagtcatt gaccagact tcacaggaga aatacagatt gttctcttca atcataatac 3960
tgctccttat cctgtgaaga aaacttacag attggctcaa attatcttg agaaatttta 4020
tactccaatc ttcatccaag aacctttcac ttcaactcaa caagggtctt caaattttgg 4080
cagtacagct aaacctctac aaatcacaga aaatatagag gttatgtctg aaacagttgc 4140
aaatcagggt gcaaaatcta gtgtgctacc acgattatat tccattcaag cacatattca 4200
tattgcacca gatattgtta tttctacaac tgocatcatt gatacaggag caacagtctg 4260

ttgtatatct gaaaagatag taccagaagc agccaaagaa cagctcaatt acaaagttaa 4320
catttctggc atttcatctc aacagcaaatt tcagcataga ctgaaaagag gtacattaga 4380
aattgcatca aataaatatg ctctaccatt gtgttatatc attgaactca atgataaaga 4440
tgatttttct atgattcttg gatgcaattt ctttaaacad atggggggag gaatgaggtt 4500
tgaaggacct catgttactt tttaaaaagg aattactacc ttgagcacct catatgcaaa 4560
tactggatc gatactgaac atgaacaaat taccagtaca acctctcagt cttttaaaga 4620
aagattttct cccttaatga atgaacttaa agcagcaggc tacattggag aagatcctct 4680
caaacattgg tctaaaaaca aagtcacatg caaattagac ctgaagaata cagagattac 4740
tattcaggat aagcccttaa gacacatcac acctgctctg gaacaatcat atggctcgtc 4800
tgtaaatgct ctactcatgc ttaagggtat tcaaccttcc aaaagtagac acagaacaat 4860
ggctttccta gtaaaactctg gcaccactgt tacagctgat ggaaaagaaa tcaaaggtaa 4920
agagcgtatg gtctttaatt acaaagccct caatgacaac acctacaaag accaatactc 4980
attaccaaatt attcagctta ttttgaaaaa ggtgatcaat agcactatct attctaaatt 5040
tgatctgaaa tctggttttc accaagttgc tatggatccc gattctgtgg aatggacagc 5100
tttcctagtt ccacaagggt tatatgaatg gctggcaatg ccttttgccc tcaaaaatgc 5160
tccagccgta tttcaaagaa aaatggatgc agtattcaaa ggggtgtgaaa aattcctcgc 5220
agtctatatt gatgatattc tgggtattttc aaacaatgag gaagatcatg caaaacacct 5280
ggcatcatg cttcagcggg gtaaagaaca tgggtcttgg ctttcaccta caaaaatgaa 5340
tattgcagtt agagaagtta attttcttgg agccactatt ggcagcagaa aagttaaact 5400
ccaagaaaat attatcaaga agatccttga ctttgataga gagaaacttc aatcaaaaaa 5460
gggtcttctg tcatctctgg gaattcttaa ctatgccga aatcatattc caaatctcgg 5520
gaaaatagcc ggacctctct attccaaaac ttccatatat ggtgatatca gattttcagc 5580
atctgattgg aagttaatca atgaaatcaa ggctattggt gagaagctcc caccacttga 5640
ttatcctcca gaacaagcct acatcattat tgaatctgat ggttgatgg aaggatgggg 5700
cgctatttgt aaatggaagc tcgcagaata tgaccccaag tcaagtgaac aaatttctgc 5760
gtatgctagt ggtaaattct ctccaatcaa atccactatc gacgcagaaa ttactgccgc 5820
catggaaggg ttagaagcat tcaagatcca ttacttggat aaacaaaaaa taaccctccg 5880
cactgattgc caggcaatca tctcattctg caacaagact tcagtcaaca agccttcacg 5940

ggtagatgg ttgaagttca ttgattatat tactaacact ggaattgatg ttaaatttga 6000
 acatattgat gctaaaaata atgtcttagc tgacactctg tccagggttag ttaacacttt 6060
 gcaggatttg ccatggctag atgaacctca tcaggatcaa acagtctccc tgatgcagga 6120
 aattgaagat gcacctcttg aatcaagca gcgttcttta acctgcttac agagactgat 6180
 ctgtagaagc ttcattggaag attctacaga agaagctatt cacttctctg aagatgataa 6240
 gatcgagcca acagctgagt catcaacccc aattactttg gatgaatttt caagaaaaag 6300
 attccaagaa catacagatc tcttagaaga atttcaatta actttgcttc aaattaatct 6360
 tcttgaagca tctcttcatg aacgattaat gaaatgccaa agttatgcaa cgagagataa 6420
 tttctgggga gattggctgc ctgaagctcg cagagatctt ttgcaaattc aactagccaa 6480
 agaaatcatc gagaagggtc gtgaaaagct tcaactctatc tag 6523

<210> 2
 <211> 7458
 <212> DNA
 <213> Taro bacilliform virus

<400> 2
 tggatcaga gctatggtga tgttttctat ggctatggca gcgtaaactt cttctgctca 60
 agaggggaagt ctaccatgtc ttttatttgc tgatgcaact tcatttaatt tgcctatatt 120
 ttgtttgata tatctcatta tttgtaagcc tcgtacttac agtacagacc gataacataa 180
 ggtaagctaa ggtagcaggc aaaagagggga acaaagtagc cgcaggagaa aggcgaagaa 240
 gtaccgtgag tcttctaccc gaaacttact aagtgttatt tctatctggg atagttagg 300
 tcttggaata taatgagacc ttacaattat atgatttata tcacatttta tggcaaagaa 360
 atttgaagca gctattaaag actggtatga taactctcga cgagcagatc tttcctatct 420
 tgacctagcc accactacaa aaccttctgc atcacaatta gtcataatc tacaagtcac 480
 ttttgataga ttatccttac attcttcagt ctccattaag gaacattacg aagtagttag 540
 caaacttcat tctttggaaa aatctataga agaattaaag tctgaattga ctacggtcaa 600
 aagggtctta acttctatcc aaaaagaagt tttcaccac aaaccctca cagcacagga 660
 agtgcaaacc cttgcacaaa gtctgatcaa agaacctag caaatagaac agcaggccgt 720
 atttcttcta aaggagctta aagaacaaac agcaaaaatt caagctttgc tccacgagct 780
 taaaagttga tgtctgtacc taattccaca taccagggt acatcaaaag tttagaagaa 840
 acaaaagtct taggagatcc atctgtagga ttctctgaaa ttcctaccac tgctatcgga 900

accgctacag gtttttcaac tctttataag cagaacaata caatcatcaa tctgcttata 960
 tctcttcata aaaagggtga tagcctctcc aaaaagacag acgtcgacga gtttagccact 1020
 gagttgtcca aactcacaat caaggatacc ccaaagggtta aggctaaaac tcctctatac 1080
 gtcttcaaga gtccccgtct tctcctcgaa gaggaagat ataaaatcgg ccttcctcct 1140
 accactaccg attggacttg gcctgtagga catccttttg ctctccacc aaaaacatcc 1200
 acaaaggcat ccacctcttc ttaaagatgt ctttagcagt tcgtgategt ggttccaacc 1260
 ctccacctc ttctacagtc cctagtcagc aggaccagat tcgggattat agaaacatgc 1320
 aaagagtgcg tcatacagcg gaaagagcag caaggagaat cttccctgga agattcaata 1380
 gaactctgga atcacaaatc aatccagagg cagaaatccg tctttctcaa caaagacgag 1440
 cagcaatggc ccacgcagaa gtattataca atacttctcc atcaacaaga aatcagaaag 1500
 tgtatcagca ctattctgaa gaaagaattc tttgtacagg acaaaatcag caattaaatt 1560
 tgccatttat taatgaatct tcttacagag ccctcagaga atcaggtaa cagcatcttc 1620
 acataggcct gatcatgatt cgtgtacatc ctcttcacgc gcgaaatgca ggaacgacag 1680
 ctcttattgt cctcgcagac ataagatgga atgatgacag atctatcatt ggcaccatgg 1740
 agatagatct cagcgccgga tcccaaattg tttatattgc cccaaatc atgctatctg 1800
 ttgaagattt ttatcgcaac atacaacttg cgattcaaac tcagggtat gaaaactgga 1860
 actctgccga gagtaacttg ctcatctctc gcgctcttat tggtcgtctg acaaacgaca 1920
 gttttacagg attccagtac aatatctcta atggtgctga gtacttgac agtcatgggtg 1980
 tgcaagctat tgaaggacaa gctcatccaa gaaccctcgg caatcgatgg atcctacaag 2040
 caccagcacc accaaggctc ctggtccac aaaacgtgga gaccaccact cttctggatg 2100
 gtaatgtgtc tatacgtttc tccaattacc atcaagcacc agttaatgat actcaggata 2160
 attctcatcc tgatatccaa gaagacgaaa accaattcat tggttttctt tctgatttgg 2220
 gggaagaata tgaattggag tctcttctt tcaactccagt tcatgcagat gaattcattt 2280
 ttataatcat taatggggaa gaaattcccg atgattttgt ctcatctttt tgttccaatt 2340
 tctctctcc accaattcca gaaccagaac ccacagccat tgaagaaaca gcttttactt 2400
 tggaagaaca attcaatgac ctggactatc ctaccctcat ttcaatggaa aaacaattag 2460
 tccagtcttc agttacttca gcttacaacc caccacaga acctcttatg ggtcaggtag 2520
 tctatccacc agcatctgca cctagaccac aagctgaaac ttcttcaacc tctgaaagat 2580
 tcaaaaattt cagagcaaag ccatatagta ccccgactat tttctacct ccagcataca 2640

atcaacaagg ggctatatatta gttcttcctg atgacattgg cttatatgaa gataccattt 2700
ctcgttggga gtccattact ctcaacatga tgaatgaaaa ggtttggcca tcaaatgaag 2760
caaaggccaa atatatggaa aatctcttag gagaaatgga gaagaagaca tggatacaat 2820
ggaggaccac atatgtatcc gaatatgatg ctttgggtcca acaaagtgat gaaacacaga 2880
acctcctgtc tcaggtaagg aggatatttc tgctacaaga cccatatcaa ggatcaactg 2940
cggaacaaga tcaggcatat aatgatcttg aaagaatttc ttgtgataat attaaggatt 3000
taattcctta tctgattcag ttccgcaatt tagctgcaaa atctggacgc ttgttcttag 3060
gtccagaatt atctgaaaaa ttattcagaa aaatgccgcc tctaataggc aaagaaattg 3120
aaacagcatt catagcaaag catggtaatg caaacatcac tgttatgcct cgcattcatt 3180
ttgcttacca ttatcttgct gaattatgta aaaaggcagc attacagaga tcattgaagg 3240
atctcagctt ctgcaaccag attcctctcc caggaatcta tacaaaaggc aacaagaagt 3300
ttgggtcttcg aaaggccaga acatacaaag gaaaaccaca tccaacacat gtacgggtat 3360
tcaaaaaggc aaaataccag cgtacaaaga agtgcaaatg ctttatatgt ggtgaaccag 3420
gacattttgc tcgagaatgc acaaagcaaa gaggaatat tgtacgagca acagtacatc 3480
aagaactggc cataccagat aattttgatg ttgtttctgt ggatgcagat gaatctgaca 3540
gctctggcat ctacagttat tcggaaaatg aagctcctct gcaagaagta aattccttca 3600
ttcatgatga aaatatcttt ttctatctg atgcagacga gtttgaaagc ccacaacagc 3660
atcttcatga aacggtaaatt atgcttcaat ctagatctgc ttatttacct caagtagctg 3720
ttggagaaga aaaattgaat tgtagtcaca tttggctaca agatgttgat attccatctg 3780
ataagcacia atgccacaca tgtagaagag aactcagaa acattacaga ctggaatgtc 3840
aaaaatgcaa attcttggtt tgctcactat gcacaattcc atatctcgga atcaccatgc 3900
aattcaggca aaagcaaaaa tctcagcctg aaaacccaaa cttagtccga gaattgttag 3960
aacatgccat ttttctagaa gaaaaatgca aaaatcaaga attactgtca gaaactcaga 4020
tagaaaggat agtcagttct gaaaaacaag tcaaatttta tggcatcctt cctacaaaaa 4080
agtccaacia atctgctggg tatgacttac aatccaacat tgatatagaa atcccgccag 4140
gaaaatgtac agtcatttct actggaacct ttctacaaat gcctgacaac atgtatggta 4200
gacttgtaga aagaacatct ttggcaatac aggggattac agtacaagga ggagtcattg 4260
accagactt cacaggagaa atacagattg ttctcttcaa tcataatact gctccttacc 4320

ctgtgaagaa aacttacaga ttggctcaaa ttatctttga gaaattttat actccaatct 4380
tcattcaaga acctttcact tcaactcaac aaggttcttc aaattttggc agtacagcta 4440
aacctctaca aatcacagaa aatatagagg ttatgtctga aacagttgca aatcagggtg 4500
caaaatctag tgtgctacca cgattatatt ccattcaagc acatattcat attgcaccag 4560
atattgttat ttctacaact gccatcattg atacaggagc aacagtctgt tgtatatctg 4620
aaaagatagt accagaagca gccaaagaac agctcaatta caaagttaac atttctggta 4680
tttcatctca acagcaaatt cagcatagac tgaaaagagg tacattagaa attgcatcaa 4740
ataaatatgc tctaccattg tgttatatca ttgaactcaa tgataaagat gatttttcta 4800
tgattcttgg atgcaatttc tttaaacata tggggggagg aatgagggtt gaaggacctc 4860
atgttacttt ttacaaagga attactacct tgagcacctc atatgcaa atctggtatcg 4920
atactgaaca tgaacaaatt accagtacaa cctctcagtc ttttaaagaa agattttctc 4980
ccttaatgaa tgaacttaaa gcagcaggct acattggaga agatcctctc aaacattggt 5040
ctaaaaacaa agtcacatgc aaattagacc tgaagaatac agagattact attcaggata 5100
agcccttaag acacatcaca cctgctctgg aacaatcata tggtcgcat gttaatgctc 5160
tactcatgct taaggttatt caacctcca aaagtagaca cagaacaatg gctttcctag 5220
taaactctgg caccactggt acagctgatg gaaaagaaat caaaggtaaa gagcgtatgg 5280
tctttaatta caaagccctc aatgacaaca cctacaaaga ccaatactca ttaccaaata 5340
ttcagcttat ttgaaaaag gtgatcaata gcactatcta ttctaaattt gatctgaaat 5400
ctggttttca ccaagttgct atggatcccg attctgtgga atggacagct ttcctagttc 5460
cacaagggtt atatgaatgg ctggcaatgc cttttggcct caaaaatgct ccagccgtat 5520
ttcaaagaaa aatggatgca gtattcaaag ggtgtgaaaa attcctcgca gtctatattg 5580
atgatattct ggtattttca acaatgagg aagatcatgc aaaacacctg gtcacatgc 5640
ttcagcgggtg taaagaacat ggtcttggtc tttcacctac aaaaatgaat attgcagtta 5700
gagaagttaa ttttcttgga gccactattg gcagcagaaa agttaaactc caagaaaata 5760
ttatcaagaa gatccttgac ttgatacag agaaacttca atcaaaaaag ggtcttcgtt 5820
cattttctggg aattcttaac tatgcccga atcatattcc aaatctcggg aaaatagccg 5880
gacctctcta ttccaaaact tccatatatg gtgatatcag attttcagca tctgattgga 5940
agttaatcaa tgaaatcaag gctattgttg agaagctccc accacttgat tatectccag 6000
aacaagccta catcattatt gaatctgat gttgtatgga aggatggggc gctatttgta 6060

```

aatggaagct cgcagaatat gaccccaagt caagtgaaca aatttgtagc tatgctagtg 6120
gtaaattctc tccaatcaaa tccactatcg acgcagaaat tactgccgcc atggaagggg 6180
tagaagcatt caagatccat tacttgata aacaaaaaat aaccctccgc actgattgcc 6240
aggcaatcat ctcatctgc aacaagactt cagtcaacaa gccttcacgg gttagatggg 6300
tgaagttcat tgattatatt actaactctg gaattgatgt taaatttgaa catattgatg 6360
ctaaaaataa tgtcttagct gacactctgt ccaggtagt taacactttg caggatttgc 6420
catggctaga tgaacctcat caggatcaaa cagtctccct gatgcaggaa attgaagatg 6480
cacctcttga aatcaagcag cgttctttaa cctgcttaca gagactgac tgtagaagct 6540
tcatggaaga ttctacagaa gaagctattc acttctcga agatgataag atcgagccaa 6600
cagctgagtc atcaacccca attactttgg atgaatttcc aagaaaaaga ttccaagaac 6660
atacagatct cttagaagaa tttcaattaa ctttgcttca aattaatctt cttgaagcat 6720
ctcttcatga acgattaatg aaatgccaaa gttatgcaac gagagataat ttctggggag 6780
attggctgcc tgaagctcgc agagatcttt tgcaaattca actagccaaa gaaatcatcg 6840
agaagggtcg tgaaaagctt cactctatct agataggatt ctttgtgtgt gaggggcgca 6900
cttgccgata atgtagtaag gaattattgt acttttacgc tggacgccac taggctccat 6960
gctttctgta atgtcacatc acttttacga attgagcctc ggggagccgt tcgtacaaag 7020
tagatgcttt tctagtcaca tctgactttt ctaaaagcag atgccatcaa ctttattoga 7080
gttgagcctc ggggagccgc tcgtttaaag atgctctttt gaaaatgaca gcgcgtgggtg 7140
cgatgtcatt ctacactttt cttaatgcg tcggccaccg actgcattat tgagattctc 7200
ttatcccttt gccacctcat cggttgcatt attgggattt cgtatcgagt cgagggacga 7260
ggcctccact actcctataa aaggacctca acccctcaga agaacggcaa gccggaaaca 7320
ccgaacttcc cattcttctc ttgagtcttt cctttgagct tgagcttggt tgtaatcttt 7380
catagtttct aagtctccga agaacgagca ccgtctcgtg aaggagccga tccttttcca 7440
accacacttt ttctacct 7458

```

```

<210> 3
<211> 146
<212> PRT
<213> Taro bacilliform virus

```

```

<400> 3

```

Met Ala Lys Lys Phe Glu Ala Ala Ile Lys Asp Trp Tyr Asp Asn Ser
1 5 10 15

Arg Arg Ala Asp Leu Ser Tyr Leu Asp Leu Ala Thr Thr Thr Lys Pro
20 25 30

Ser Ala Ser Gln Leu Ala His Asn Leu Gln Val Ile Phe Asp Arg Leu
35 40 45

Ser Leu His Ser Ser Val Ser Ile Lys Glu His Tyr Glu Val Val Ser
50 55 60

Lys Leu His Ser Leu Glu Lys Ser Ile Glu Glu Leu Lys Ser Glu Leu
65 70 75 80

Thr Thr Val Lys Arg Ala Leu Thr Ser Ile Gln Lys Glu Val Phe Thr
85 90 95

His Lys Pro Leu Thr Ala Gln Glu Val Gln Thr Leu Ala Gln Ser Leu
100 105 110

Ile Lys Glu Pro Lys Gln Ile Glu Gln Gln Ala Val Phe Leu Leu Lys
115 120 125

Glu Leu Lys Glu Gln Thr Ala Lys Ile Gln Ala Leu Leu His Glu Leu
130 135 140

Lys Ser
145

<210> 4
<211> 144
<212> PRT
<213> Taro bacilliform virus

<400> 4

Met Ser Val Pro Asn Ser Thr Tyr Pro Gly Tyr Ile Lys Ser Leu Glu
1 5 10 15

Glu Thr Lys Val Leu Gly Asp Pro Ser Val Gly Phe Ser Glu Ile Pro
20 25 30

Thr Thr Ala Ile Gly Thr Ala Thr Gly Phe Ser Thr Leu Tyr Lys Gln
35 40 45

Asn Asn Thr Ile Ile Asn Leu Leu Ile Ser Leu His Lys Lys Val Asp
50 55 60

Ser Leu Ser Lys Lys Thr Asp Val Asp Glu Leu Ala Thr Glu Leu Ser
65 70 75 80

Lys Leu Thr Ile Lys Asp Thr Pro Lys Val Lys Ala Lys Thr Pro Leu
85 90 95

Tyr Val Phe Lys Ser Pro Arg Leu Ile Leu Glu Glu Glu Arg Tyr Lys
100 105 110

Ile Gly Leu Pro Pro Thr Thr Thr Asp Trp Thr Trp Pro Val Gly His
115 120 125

Pro Phe Ala Pro Pro Pro Lys Thr Ser Thr Lys Ala Ser Thr Ser Ser
130 135 140

<210> 5
<211> 1881
<212> PRT
<213> Taro bacilliform virus

<400> 5

Met Ser Leu Ala Val Arg Asp Arg Gly Ser Asn Pro Ser Thr Ser Ser
1 5 10 15

Thr Val Pro Ser Gln Gln Asp Gln Ile Arg Asp Tyr Arg Asn Met Gln
20 25 30

Arg Val Arg His Thr Ala Glu Arg Ala Ala Arg Arg Ile Phe Pro Gly
35 40 45

Arg Phe Asn Arg Thr Leu Glu Ser Gln Ile Asn Pro Glu Ala Glu Ile
50 55 60

Arg Leu Ser Gln Gln Arg Arg Ala Ala Met Val Pro Ala Glu Val Leu
65 70 75 80

Tyr Asn Thr Ser Pro Ser Thr Arg Asn Gln Lys Val Tyr Gln His Tyr
85 90 95

Ser Glu Glu Arg Ile Leu Cys Thr Gly Gln Asn Gln Gln Leu Asn Leu
 100 105 110

Pro Phe Ile Asn Glu Ser Ser Tyr Arg Ala Leu Arg Glu Ser Gly Gln
 115 120 125

Gln His Leu His Ile Gly Leu Ile Met Ile Arg Val His Pro Leu His
 130 135 140

Arg Arg Asn Ala Gly Thr Thr Ala Leu Ile Val Pro Arg Asp Ile Arg
 145 150 155 160

Trp Asn Asp Asp Arg Ser Ile Ile Gly Thr Met Glu Ile Asp Leu Ser
 165 170 175

Ala Gly Ser Gln Ile Val Tyr Ile Ala Pro Asn Ile Met Leu Ser Val
 180 185 190

Glu Asp Phe Tyr Arg Asn Ile Gln Leu Ala Ile Gln Thr Gln Gly Tyr
 195 200 205

Glu Asn Trp Asn Ser Ala Glu Ser Asn Leu Leu Ile Ser Arg Ala Leu
 210 215 220

Ile Gly Arg Leu Thr Asn Asp Ser Phe Thr Gly Phe Gln Tyr Asn Ile
 225 230 235 240

Ser Asn Val Ala Glu Tyr Leu His Ser His Gly Val Gln Ala Ile Glu
 245 250 255

Gly Gln Ala His Pro Arg Thr Leu Gly Asn Arg Trp Ile Leu Gln Ala
 260 265 270

Pro Ala Pro Pro Arg Ser Leu Val Pro Gln Asn Val Glu Thr Thr Thr
 275 280 285

Leu Leu Asp Gly Asn Val Ser Ile Arg Phe Ser Asn Tyr His Gln Ala
 290 295 300

Pro Val Asn Asp Thr Gln Asp Asn Ser His Pro Asp Ile Gln Glu Asp
 305 310 315 320

Glu Asn Gln Phe Ile Gly Phe Leu Ser Asp Leu Gly Glu Glu Tyr Glu

325	330	335
Leu Glu Tyr Pro Ser Phe Thr Pro Val His Ala Asp Glu Phe Ile Phe 340 345 350		
Ile Ile Ile Asn Gly Glu Glu Ile Pro Asp Asp Phe Val Ser Ser Phe 355 360 365		
Cys Ser Asn Phe Ser Pro Pro Pro Ile Pro Glu Pro Glu Pro Thr Ala 370 375 380		
Ile Glu Glu Thr Ala Phe Thr Leu Glu Glu Gln Phe Asn Asp Leu Asp 385 390 395 400		
Tyr Pro Thr Leu Ile Ser Met Glu Lys Gln Leu Val Gln Ser Ser Val 405 410 415		
Thr Ser Ala Tyr Asn Pro Pro Thr Glu Pro Leu Met Gly Gln Val Val 420 425 430		
Tyr Pro Pro Ala Ser Ala Pro Arg Pro Gln Ala Glu Thr Ser Ser Thr 435 440 445		
Ser Glu Arg Phe Lys Asn Phe Arg Ala Lys Pro Tyr Ser Thr Pro Thr 450 455 460		
Ile Phe Leu Pro Pro Ala Tyr Asn Gln Gln Gly Ala Ile Leu Val Leu 465 470 475 480		
Pro Asp Asp Ile Gly Leu Tyr Glu Asp Thr Ile Ser Arg Trp Glu Ser 485 490 495		
Ile Thr Leu Asn Met Met Asn Glu Lys Val Trp Pro Ser Asn Glu Ala 500 505 510		
Lys Ala Lys Tyr Met Glu Asn Leu Leu Gly Glu Met Glu Lys Lys Thr 515 520 525		
Trp Ile Gln Trp Arg Thr Thr Tyr Val Ser Glu Tyr Asp Ala Leu Val 530 535 540		
Gln Gln Ser Asp Glu Thr Gln Asn Leu Leu Ser Gln Val Arg Arg Ile 545 550 555 560		

Phe Leu Leu Gln Asp Pro Tyr Gln Gly Ser Thr Ala Glu Gln Asp Gln
565 570 575

Ala Tyr Asn Asp Leu Glu Arg Ile Ser Cys Asp Asn Ile Lys Asp Leu
580 585 590

Ile Pro Tyr Leu Ile Gln Phe Arg Asn Leu Ala Ala Lys Ser Gly Arg
595 600 605

Leu Phe Leu Gly Pro Glu Leu Ser Glu Lys Leu Phe Arg Lys Met Pro
610 615 620

Pro Leu Ile Gly Lys Glu Ile Glu Thr Ala Phe Ile Ala Lys His Gly
625 630 635 640

Asn Ala Asn Ile Thr Val Met Pro Arg Ile His Phe Ala Tyr His Tyr
645 650 655

Leu Ala Glu Leu Cys Lys Lys Ala Ala Leu Gln Arg Ser Leu Lys Asp
660 665 670

Leu Ser Phe Cys Asn Gln Ile Pro Leu Pro Gly Ile Tyr Thr Lys Gly
675 680 685

Asn Lys Lys Phe Gly Leu Arg Lys Ala Arg Thr Tyr Lys Gly Lys Pro
690 695 700

His Pro Thr His Val Arg Val Phe Lys Lys Ala Lys Tyr Gln Arg Thr
705 710 715 720

Lys Lys Cys Lys Cys Phe Ile Cys Gly Glu Pro Gly His Phe Ala Arg
725 730 735

Glu Cys Thr Lys Gln Arg Gly Asn Ile Val Arg Ala Thr Val His Gln
740 745 750

Glu Leu Ala Ile Pro Asp Asn Phe Asp Val Val Ser Val Asp Ala Asp
755 760 765

Glu Ser Asp Ser Ser Gly Ile Tyr Ser Tyr Ser Glu Asn Glu Ala Pro
770 775 780

Leu Gln Glu Val Asn Ser Phe Ile His Asp Glu Asn Ile Phe Phe Leu
785 790 795 800

Ser Asp Ala Asp Glu Phe Glu Ser Pro Gln Gln His Leu His Glu Thr
805 810 815

Val Asn Met Leu Gln Ser Arg Ser Ala Tyr Leu Pro Gln Val Ala Val
820 825 830

Gly Glu Glu Lys Leu Asn Cys Ser His Ile Trp Leu Gln Asp Val Asp
835 840 845

Ile Pro Ser Asp Lys His Lys Cys His Thr Cys Arg Arg Asp Thr Gln
850 855 860

Lys His Tyr Arg Leu Glu Cys Gln Lys Cys Lys Phe Leu Val Cys Ser
865 870 875 880

Leu Cys Thr Ile Pro Tyr Leu Gly Ile Thr Met Gln Phe Arg Gln Lys
885 890 895

Gln Lys Ser Gln Pro Glu Asn Pro Asn Leu Val Arg Glu Leu Leu Glu
900 905 910

His Ala Ile Phe Leu Glu Glu Lys Cys Lys Asn Gln Glu Leu Leu Ser
915 920 925

Glu Thr Gln Ile Glu Arg Ile Val Ser Ser Glu Lys Gln Val Lys Phe
930 935 940

Tyr Gly Ile Leu Pro Thr Lys Lys Ser Asn Lys Ser Ala Gly Tyr Asp
945 950 955 960

Leu Gln Ser Asn Ile Asp Ile Glu Ile Pro Pro Gly Lys Cys Thr Val
965 970 975

Ile Ser Thr Gly Thr Phe Leu Gln Met Pro Asp Asn Met Tyr Gly Arg
980 985 990

Leu Val Glu Arg Thr Ser Leu Ala Ile Gln Gly Ile Thr Val Gln Gly
995 1000 1005

Gly Val Ile Asp Pro Asp Phe Thr Gly Glu Ile Gln Ile Val Leu
 1010 1015 1020

Phe Asn His Asn Thr Ala Pro Tyr Pro Val Lys Lys Thr Tyr Arg
 1025 1030 1035

Leu Ala Gln Ile Ile Phe Glu Lys Phe Tyr Thr Pro Ile Phe Ile
 1040 1045 1050

Gln Glu Pro Phe Thr Ser Thr Gln Gln Gly Ser Ser Asn Phe Gly
 1055 1060 1065

Ser Thr Ala Lys Pro Leu Gln Ile Thr Glu Asn Ile Glu Val Met
 1070 1075 1080

Ser Glu Thr Val Ala Asn Gln Val Ala Lys Ser Ser Val Leu Pro
 1085 1090 1095

Arg Leu Tyr Ser Ile Gln Ala His Ile His Ile Ala Pro Asp Ile
 1100 1105 1110

Val Ile Ser Thr Thr Ala Ile Ile Asp Thr Gly Ala Thr Val Cys
 1115 1120 1125

Cys Ile Ser Glu Lys Ile Val Pro Glu Ala Ala Lys Glu Gln Leu
 1130 1135 1140

Asn Tyr Lys Val Asn Ile Ser Gly Ile Ser Ser Gln Gln Gln Ile
 1145 1150 1155

Gln His Arg Leu Lys Arg Gly Thr Leu Glu Ile Ala Ser Asn Lys
 1160 1165 1170

Tyr Ala Leu Pro Leu Cys Tyr Ile Ile Glu Leu Asn Asp Lys Asp
 1175 1180 1185

Asp Phe Ser Met Ile Leu Gly Cys Asn Phe Phe Lys His Met Gly
 1190 1195 1200

Gly Gly Met Arg Phe Glu Gly Pro His Val Thr Phe Tyr Lys Gly
 1205 1210 1215

Ile Thr Thr Leu Ser Thr Ser Tyr Ala Asn Thr Gly Ile Asp Thr

1220	1225	1230
Glu His Glu Gln Ile Thr Ser Thr Thr Ser Gln Ser Phe Lys Glu		
1235	1240	1245
Arg Phe Ser Pro Leu Met Asn Glu Leu Lys Ala Ala Gly Tyr Ile		
1250	1255	1260
Gly Glu Asp Pro Leu Lys His Trp Ser Lys Asn Lys Val Thr Cys		
1265	1270	1275
Lys Leu Asp Leu Lys Asn Thr Glu Ile Thr Ile Gln Asp Lys Pro		
1280	1285	1290
Leu Arg His Ile Thr Pro Ala Leu Glu Gln Ser Tyr Gly Arg His		
1295	1300	1305
Val Asn Ala Leu Leu Met Leu Lys Val Ile Gln Pro Ser Lys Ser		
1310	1315	1320
Arg His Arg Thr Met Ala Phe Leu Val Asn Ser Gly Thr Thr Val		
1325	1330	1335
Thr Ala Asp Gly Lys Glu Ile Lys Gly Lys Glu Arg Met Val Phe		
1340	1345	1350
Asn Tyr Lys Ala Leu Asn Asp Asn Thr Tyr Lys Asp Gln Tyr Ser		
1355	1360	1365
Leu Pro Asn Ile Gln Leu Ile Leu Lys Lys Val Ile Asn Ser Thr		
1370	1375	1380
Ile Tyr Ser Lys Phe Asp Leu Lys Ser Gly Phe His Gln Val Ala		
1385	1390	1395
Met Asp Pro Asp Ser Val Glu Trp Thr Ala Phe Leu Val Pro Gln		
1400	1405	1410
Gly Leu Tyr Glu Trp Leu Ala Met Pro Phe Gly Leu Lys Asn Ala		
1415	1420	1425
Pro Ala Val Phe Gln Arg Lys Met Asp Ala Val Phe Lys Gly Cys		
1430	1435	1440

Glu Lys Phe Leu Ala Val Tyr Ile Asp Asp Ile Leu Val Phe Ser
1445 1450 1455

Asn Asn Glu Glu Asp His Ala Lys His Leu Val Ile Met Leu Gln
1460 1465 1470

Arg Cys Lys Glu His Gly Leu Val Leu Ser Pro Thr Lys Met Asn
1475 1480 1485

Ile Ala Val Arg Glu Val Asn Phe Leu Gly Ala Thr Ile Gly Ser
1490 1495 1500

Arg Lys Val Lys Leu Gln Glu Asn Ile Ile Lys Lys Ile Leu Asp
1505 1510 1515

Phe Asp Thr Glu Lys Leu Gln Ser Lys Lys Gly Leu Arg Ser Phe
1520 1525 1530

Leu Gly Ile Leu Asn Tyr Ala Arg Asn His Ile Pro Asn Leu Gly
1535 1540 1545

Lys Ile Ala Gly Pro Leu Tyr Ser Lys Thr Ser Ile Tyr Gly Asp
1550 1555 1560

Ile Arg Phe Ser Ala Ser Asp Trp Lys Leu Ile Asn Glu Ile Lys
1565 1570 1575

Ala Ile Val Glu Lys Leu Pro Pro Leu Asp Tyr Pro Pro Glu Gln
1580 1585 1590

Ala Tyr Ile Ile Ile Glu Ser Asp Gly Cys Met Glu Gly Trp Gly
1595 1600 1605

Ala Ile Cys Lys Trp Lys Leu Ala Glu Tyr Asp Pro Lys Ser Ser
1610 1615 1620

Glu Gln Ile Cys Ala Tyr Ala Ser Gly Lys Phe Ser Pro Ile Lys
1625 1630 1635

Ser Thr Ile Asp Ala Glu Ile Thr Ala Ala Met Glu Gly Leu Glu
1640 1645 1650

Ala Phe Lys Ile His Tyr Leu Asp Lys Gln Lys Ile Thr Leu Arg
1655 1660 1665

Thr Asp Cys Gln Ala Ile Ile Ser Phe Cys Asn Lys Thr Ser Val
1670 1675 1680

Asn Lys Pro Ser Arg Val Arg Trp Leu Lys Phe Ile Asp Tyr Ile
1685 1690 1695

Thr Asn Thr Gly Ile Asp Val Lys Phe Glu His Ile Asp Ala Lys
1700 1705 1710

Asn Asn Val Leu Ala Asp Thr Leu Ser Arg Leu Val Asn Thr Leu
1715 1720 1725

Gln Asp Leu Pro Trp Leu Asp Glu Pro His Gln Asp Gln Thr Val
1730 1735 1740

Ser Leu Met Gln Glu Ile Glu Asp Ala Pro Leu Glu Ile Lys Gln
1745 1750 1755

Arg Ser Leu Thr Cys Leu Gln Arg Leu Ile Cys Arg Ser Phe Met
1760 1765 1770

Glu Asp Ser Thr Glu Glu Ala Ile His Phe Leu Glu Asp Asp Lys
1775 1780 1785

Ile Glu Pro Thr Ala Glu Ser Ser Thr Pro Ile Thr Leu Asp Glu
1790 1795 1800

Phe Ser Arg Lys Arg Phe Gln Glu His Thr Asp Leu Leu Glu Glu
1805 1810 1815

Phe Gln Leu Thr Leu Leu Gln Ile Asn Leu Leu Glu Ala Ser Leu
1820 1825 1830

His Glu Arg Leu Met Lys Cys Gln Ser Tyr Ala Thr Arg Asp Asn
1835 1840 1845

Phe Trp Gly Asp Trp Leu Pro Glu Ala Arg Arg Asp Leu Leu Gln
1850 1855 1860

Ile Gln Leu Ala Lys Glu Ile Ile Glu Lys Val Arg Glu Lys Leu
 1865 1870 1875

His Ser Ile
 1880

<210> 6
 <211> 1190
 <212> DNA
 <213> Taro bacilliform virus

<400> 6
 gccttcacgg gttagatggt tgaagttcat tgattatatt actaacactg gaattgatgt 60
 taaatttgaa catattgatg ctaaaaataa tgtcttagct gacactctgt ccagggttagt 120
 taacactttg caggatttgc catggctaga tgaacctcat caggatcaaa cagtctccct 180
 gatgcaggaa attgaagatg cacctcttga aatcaagcag cgttctttaa cctgcttaca 240
 gagactgata tgtagaagct tcatggaaga ttctacagaa gaagctattc acttcctcga 300
 agatgataag atcgagccaa cagctgagtc atcaacccca attactttgg atgaattttc 360
 aagaaaaaga ttccaagaac atacagatct cttagaagaa tttcaattaa ctttgcttca 420
 aattaatctt cttgaagcat ctcttcatga acgattaatg aaatgccaaa gttatgcaac 480
 gagagataat ttctggggag attggctgcc tgaagctcgc agagatcttt tgcaaattca 540
 actagccaaa gaaatcatcg agaaggttcg tgaaaagctt cactctatct agataggatt 600
 ctttgtgtgt gagtggcgca cttgcgcata atgtagtaag gaattattgt actttttacgc 660
 tggacgccac taggctccat gctttctgta atgtcacatc actttttacga attgagcctc 720
 ggggagccgt tcgtacaaag tagatgcttt tctagtcaca tctgactttt ctaaaagcag 780
 atgccatcaa cttttattcga gttgagcctc ggggagccgc tcgtttaaag atgctctttt 840
 gaaaatgaca gcgcgtggtg cgatgtcatt ctcacctttt ctttaatgcy tcggccaccg 900
 actgcattat tgagattctc ttatcccttt gccacctcat cggttgcatt attgggattt 960
 cgtatcgagt cgagggacga ggcctccact actcctataa aaggacctca acccctcaga 1020
 agaacggcaa gccggaaaca ccgaacttcc cattcttctc ttgagtcttt cctttgagct 1080
 tgagcttgtg tgtaatcttt catagtcttct aagtctccga agaacgagca ccgtctcgtg 1140
 aaggagccga tcctttttcca accacacttt ttctaccttg gtatcagagc 1190

<210> 7
 <211> 598

<212> DNA

<213> Taro bacilliform virus

<400> 7

```

ataggattct ttgtgtgtga gtggcgact tgcgcataat gtagtaagga attattgtac      60
ttttacgctg gacgccacta ggctccatgc tttctgtaat gtcacatcac ttttacgaat      120
tgagcctcgg ggagccgttc gtacaaagta gatgcttttc tagtcacatc tgacttttct      180
aaaagcagat gccatcaact ttattcgagt tgagcctcgg ggagccgctc gtttaaagat      240
gctcttttga aaatgacagc gcgtgggtgcg atgtcattct caccttttct ttaatgcgtc      300
ggccaccgac tgcattattg agattctctt atccctttgc cacctcatcg gttgcattat      360
tgggatttcg tatcgagtcg agggacgagg cctccactac tcctataaaa ggacctcaac      420
ccctcagaag aacggcaagc cggaaacacc gaacttccca ttcttctctt gagtctttcc      480
tttgagcttg agcttgtgtg taatctttca tagtttctaa gtctccgaag aacgagcacc      540
gtctcgtgaa ggagccgatc cttttccaac cacacttttt ctaccttggg atcagagc      598

```

<210> 8

<211> 529

<212> DNA

<213> Taro bacilliform virus

<400> 8

```

ggagcgccact aggctccatg ctttctgtaa tgtcacatca cttttacgaa ttgagcctcg      60
gggagccggtt cgtacaaagt agatgctttt ctagtcacat ctgacttttc taaaagcaga      120
tgccatcaac tttattcgag ttgagcctcg gggagccgct cgtttaaaga tgctcttttg      180
aaaatgacag cgcgtgggtgc gatgtcattc tcaccttttc tttaatgcgt cggccaccga      240
ctgcattatt gagattctct tatccctttg ccacctcatc gggtgcatta ttgggatttc      300
gtatcgagtc gagggacgag gcctccacta ctcctataaa aggacctcaa ccctcagaa      360
gaacggcaag ccggaaacac cgaacttccc attcttctct tgagtcttcc ctttgagctt      420
gagcttgtgt gtaatctttc atagtttcta agtctccgaa gaacgagcac cgtctcgtga      480
aggagccgat ccttttccaa ccacactttt tctaccttgg tatcagagc      529

```

<210> 9

<211> 261

<212> DNA

<213> Taro bacilliform virus

<400> 9

```

tgccacctca tcggttgcatt tattgggatt tcgtatcgag tcgagggacg aggcctccac      60

```

tactcctata aaaggacctc aaccctcag aagaacggca agccggaaac accgaacttc 120
ccattcttct cttgagtctt tcctttgagc ttgagcttgt gtgtaatctt tcatagtttc 180
taagtctccg aagaacgagc accgtctcgt gaaggagccg atccttttcc aaccacactt 240
tttctacctt ggtatcagag c 261

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Badna FP primer

<220>
<221> modified_base
<222> (5)..(6)
<223> I

<220>
<221> modified_base
<222> (10)..(11)
<223> I

<220>
<221> modified_base
<222> (18)..(19)
<223> I

<400> 10
atgccttygg aaraaygcc 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Badna RP primer

<220>
<221> modified_base
<222> (9)..(10)
<223> I

<220>
<221> modified_base
<222> (11)..(12)
<223> I

<220>
<221> modified_base
<222> (13)..(14)
<223> I

<220>
<221> modified_base
<222> (18)..(19)
<223> I

<400> 11
ccayttrcaa cscgccacc

20

<210> 12
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<223> 1F primer

<400> 12
ggatgcagta ttcaaagggt gtg

23

<210> 13
<211> 26
<212> DNA
<213> Artificial Sequence

<220>

<223> TRBR primer

<400> 13
ctgcaggcgg ccgcgctctg atacca

26

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> 5F primer

<400> 14
agtctttcct ttgagcttga gc

22

<210> 15
<211> 25
<212> DNA
<213> Artificial Sequence

<220>

<223> G2R primer

<400> 15

cacacccttt gaatactgca tccat

25

<210> 16

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Cytoplasmic initiator methionine tRNA (tRNA^{met}) binding site

<400> 16

tggtatcaga gc

12

<210> 17

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> F-GTN primer

<400> 17

ctgcagatag gattctttgt gtgtg

25

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> R-GTN primer

<400> 18

ccatgggctc tgataccaag gtag

24

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> P527-F primer

<400> 19

ctgcagggac gccactaggc

20

<210> 20

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> P257-F primer

<400> 20

ctgcaggcca cctcatcggt tgc

23

<210> 21

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> P114-F primer

<400> 21

ctgcaggagc ttgagcttgt gtg

23

<210> 22

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> FP-as-1 primer

<400> 22

ctgcaggcct tcacgggtta gatg

24

<210> 23

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> TRBR-Bam primer

<400> 23

ggatccgctc tgataccaag gtag

24

<210> 24

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> FP-6765-pro primer

<400> 24

ctgcaggggg agattggctg c

21

<210> 25
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> P600Not-F primer

<400> 25
ggaagcttgc ggccgccgag aaggttcg

28

<210> 26
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> P600Bgl-R primer

<400> 26
gcggaagatc ttgctctgat accaaggtag

30

<210> 27
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> RP-leader primer

<400> 27
ccatggatca tataattgta aggtcgc

27

<210> 28
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> GUS1 primer

<400> 28
atgtttacgt cctgt

15

<210> 29
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> GUS2 primer

<400> 29
ttacttggtt gc

12

27

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.